Cover
Cover - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Feb. 21, 2024 | Jun. 30, 2023 | |
Cover [Abstract] | |||
Document Type | 10-K | ||
Document Annual Report | true | ||
Document Period End Date | Dec. 31, 2023 | ||
Current Fiscal Year End Date | --12-31 | ||
Document Transition Report | false | ||
Document Financial Statement Error Correction [Flag] | false | ||
Entity File Number | 001-34180 | ||
Entity Registrant Name | STANDARD BIOTOOLS INC. | ||
Entity Incorporation, State or Country Code | DE | ||
Entity Tax Identification Number | 77-0513190 | ||
Entity Address, Address Line One | 2 Tower Place, Suite 2000 | ||
Entity Address, City or Town | South San Francisco, | ||
Entity Address, State or Province | CA | ||
Entity Address, Postal Zip Code | 94080 | ||
City Area Code | 650 | ||
Local Phone Number | 266-6000 | ||
Title of 12(b) Security | Common Stock, $0.001 par value per share | ||
Trading Symbol | LAB | ||
Security Exchange Name | NASDAQ | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Non-accelerated Filer | ||
Entity Small Business | true | ||
Entity Emerging Growth Company | false | ||
ICFR Auditor Attestation Flag | false | ||
Entity Shell Company | false | ||
Entity Public Float | $ 132.7 | ||
Entity Common Stock, Shares Outstanding (shares) | 290,117,930 | ||
Documents Incorporated by Reference | Portions of the registrant’s proxy statement in connection with the registrant’s annual meeting of stockholders, scheduled to be held in June 2024, are incorporated by reference in Part III of this report. Except as expressly incorporated by reference, such proxy statement shall not be deemed to be part of this report. | ||
Amendment Flag | false | ||
Document Fiscal Year Focus | 2023 | ||
Document Fiscal Period Focus | FY | ||
Entity Central Index Key | 0001162194 |
Audit Information
Audit Information | 12 Months Ended |
Dec. 31, 2023 | |
Audit Information [Abstract] | |
Auditor Name | PricewaterhouseCoopers LLP |
Auditor Location | San Jose, California |
Auditor Firm ID | 238 |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Current assets: | ||
Cash and cash equivalents | $ 51,704 | $ 81,309 |
Short-term investments | 63,191 | 84,475 |
Accounts receivable (net of allowances of $312 and $592 at December 31, 2023 and 2022, respectively) | 19,660 | 17,280 |
Inventories, net | 20,533 | 21,473 |
Prepaid expenses and other current assets | 3,127 | 4,278 |
Total current assets | 158,215 | 208,815 |
Property and equipment, net | 24,187 | 25,652 |
Operating lease right-of-use asset, net | 30,663 | 33,883 |
Other non-current assets | 2,285 | 3,109 |
Developed technology, net | 1,400 | 12,600 |
Goodwill | 106,317 | 106,251 |
Total assets | 323,067 | 390,310 |
Current liabilities: | ||
Accounts payable | 9,236 | 7,914 |
Accrued compensation and related benefits | 11,867 | 9,153 |
Operating lease liabilities, current | 4,323 | 3,682 |
Deferred revenue, current | 11,607 | 10,792 |
Deferred grant income, current | 3,612 | 3,644 |
Other accrued liabilities | 9,152 | 6,175 |
Term loan, current | 5,000 | 2,083 |
Convertible notes, current | 54,530 | 0 |
Total current liabilities | 109,327 | 43,443 |
Convertible notes, non-current | 569 | 54,615 |
Term loan, non-current | 3,414 | 8,194 |
Deferred tax liability | 841 | 1,055 |
Operating lease liabilities, non-current | 30,374 | 34,081 |
Deferred revenue, non-current | 3,520 | 3,816 |
Deferred grant income, non-current | 10,755 | 14,359 |
Other non-current liabilities | 1,065 | 961 |
Total liabilities | 159,865 | 160,524 |
Commitments and contingencies (Note 8) | ||
Mezzanine equity: | ||
Redeemable preferred stock: $0.001 par value; 256 shares authorized, issued and outstanding at December 31, 2023 and 2022; aggregate liquidation preference of $255,559 at December 31, 2023 and 2022 | 311,253 | 311,253 |
Stockholders' deficit: | ||
Preferred stock: $0.001 par value, 9,744 shares authorized at December 31, 2023 and 2022; no shares issued and outstanding at December 31, 2023 and 2022 | 0 | 0 |
Common stock: $0.001 par value, 400,000 shares authorized at December 31, 2023 and 2022; 83,364 and 79,904 shares issued at December 31, 2023 and 2022, respectively; 80,232 and 79,482 shares outstanding at December 31, 2023 and 2022, respectively | 83 | 80 |
Additional paid-in capital | 860,816 | 847,008 |
Accumulated other comprehensive loss | (2,221) | (1,896) |
Accumulated deficit | (1,000,752) | (926,096) |
Treasury stock at cost: 3,132 and 422 shares at December 31, 2023 and 2022, respectively | (5,977) | (563) |
Total stockholders' deficit | (148,051) | (81,467) |
Total liabilities, mezzanine equity and stockholders' deficit | $ 323,067 | $ 390,310 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Statement of Financial Position [Abstract] | ||
Accounts receivable, allowances | $ 312 | $ 592 |
Redeemable preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Redeemable preferred stock, shares authorized (in shares) | 256,000 | 256,000 |
Redeemable preferred stock, shares issued (in shares) | 256,000 | 256,000 |
Redeemable preferred stock, shares outstanding (in shares) | 256,000 | 256,000 |
Redeemable preferred stock, aggregate liquidation preference | $ 255,559 | $ 255,559 |
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized (in shares) | 9,744,000 | 9,744,000 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares authorized (in shares) | 400,000,000 | 400,000,000 |
Common stock, shares issued (in shares) | 83,364,000 | 79,904,000 |
Common stock, shares outstanding (in shares) | 80,232,000 | 79,482,000 |
Treasury stock (in shares) | 3,132,000 | 422,000 |
Accumulated other comprehensive loss | $ (2,221) | $ (1,896) |
Consolidated Statements of Oper
Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Revenue: | ||
Total revenue | $ 106,340 | $ 97,948 |
Cost of revenue: | ||
Total cost of revenue | 55,890 | 60,897 |
Gross profit | 50,450 | 37,051 |
Research and development | 25,948 | 37,382 |
Selling, general and administrative | 87,541 | 102,285 |
Restructuring and related charges | 7,076 | 9,732 |
Transaction-related expenses | 6,485 | 3,857 |
Total operating expenses | 127,050 | 153,256 |
Loss from operations | (76,600) | (116,205) |
Interest expense | (4,567) | (4,331) |
Loss on forward sale of Series B Preferred Stock | 0 | (60,081) |
Loss on Bridge Loans | 0 | (13,719) |
Other income (expense), net | 6,963 | 1,408 |
Loss before income taxes | (74,204) | (192,928) |
Income tax benefit (expense) | (452) | 2,830 |
Net loss | $ (74,656) | $ (190,098) |
Net loss per share, basic (in dollars per share) | $ (0.94) | $ (2.43) |
Net loss per share, diluted (in dollars per share) | $ (0.94) | $ (2.43) |
Shares used in computing net loss per share, basic (in shares) | 79,160 | 78,305 |
Shares used in computing net loss per share, diluted (in shares) | 79,160 | 78,305 |
Service revenue | ||
Revenue: | ||
Total revenue | $ 25,980 | $ 23,712 |
Product revenue | ||
Revenue: | ||
Total revenue | 79,198 | 72,454 |
Cost of revenue: | ||
Total cost of revenue | 44,942 | 52,555 |
Service and other revenue | ||
Revenue: | ||
Total revenue | 27,142 | 25,494 |
Cost of revenue: | ||
Total cost of revenue | 10,948 | 8,342 |
Other revenue | ||
Revenue: | ||
Total revenue | $ 1,162 | $ 1,782 |
Consolidated Statements of Comp
Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Statement of Comprehensive Income [Abstract] | ||
Net loss | $ (74,656) | $ (190,098) |
Other comprehensive income (loss), net of tax: | ||
Foreign currency translation adjustment | (849) | (487) |
Net change in unrealized gain (loss) on investments | 524 | (502) |
Other comprehensive income (loss), net of tax | (325) | (989) |
Comprehensive loss | $ (74,981) | $ (191,087) |
Consolidated Statements of Stoc
Consolidated Statements of Stockholders' Equity (Deficit) - USD ($) $ in Thousands | Total | Common Stock | Additional Paid-in Capital | Accum. Other Comp. (Loss) | Accum. Deficit | Treasury Stock |
Beginning balance (in shares) at Dec. 31, 2021 | 76,919,000 | |||||
Beginning balance at Dec. 31, 2021 | $ 94,596 | $ 77 | $ 831,424 | $ (907) | $ (735,998) | |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Issuance of restricted stock, net of shares withheld for taxes (in shares) | 2,373,000 | |||||
Issuance of restricted stock, net of shares withheld for taxes | (211) | $ 2 | (213) | |||
Issuance of common stock under ESPP (in shares) | 583,000 | |||||
Issuance of common stock under ESPP | 820 | $ 1 | 819 | |||
Issuance of common stock from stock option exercises (in shares) | 29,000 | |||||
Issuance of common stock from stock option exercises | 98 | 98 | ||||
Stock-based compensation expense | 14,880 | 14,880 | ||||
Repurchase of common stock (in shares) | (422,000) | |||||
Repurchase of common stock | (563) | $ (563) | ||||
Net loss | (190,098) | (190,098) | ||||
Other comprehensive loss, net of tax | $ (989) | (989) | 0 | |||
Ending balance (in shares) at Dec. 31, 2022 | 79,482,000 | 79,904,000 | ||||
Ending balance at Dec. 31, 2022 | $ (81,467) | $ 80 | 847,008 | (1,896) | (926,096) | $ (563) |
Treasury stock, ending balance (in shares) at Dec. 31, 2022 | 422,000 | (422,000) | ||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Issuance of restricted stock, net of shares withheld for taxes (in shares) | 2,946,000 | |||||
Issuance of restricted stock, net of shares withheld for taxes | $ (116) | $ 3 | (119) | |||
Issuance of common stock under ESPP (in shares) | 470,000 | |||||
Issuance of common stock under ESPP | $ 723 | 723 | ||||
Issuance of common stock from stock option exercises (in shares) | 44,000 | 44,000 | ||||
Issuance of common stock from stock option exercises | $ 81 | 81 | ||||
Stock-based compensation expense | $ 13,123 | 13,123 | ||||
Repurchase of common stock (in shares) | 2,709,703 | (2,710,000) | ||||
Repurchase of common stock | $ (5,414) | $ (5,414) | ||||
Net loss | (74,656) | (74,656) | ||||
Other comprehensive loss, net of tax | $ (325) | (325) | ||||
Ending balance (in shares) at Dec. 31, 2023 | 80,232,000 | 83,364,000 | ||||
Ending balance at Dec. 31, 2023 | $ (148,051) | $ 83 | $ 860,816 | $ (2,221) | $ (1,000,752) | $ (5,977) |
Treasury stock, ending balance (in shares) at Dec. 31, 2023 | 3,132,000 | (3,132,000) |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Operating activities | ||
Net loss | $ (74,656) | $ (190,098) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Loss on forward sale of Series B Preferred Stock | 0 | 60,081 |
Loss on bridge loans | 0 | 13,719 |
Stock-based compensation expense | 13,123 | 14,880 |
Amortization of developed technology | 11,200 | 11,528 |
Depreciation and amortization | 3,980 | 3,499 |
Provision for excess and obsolete inventory | 1,496 | 7,874 |
Impairment of InstruNor developed technology intangible | 0 | 3,526 |
Amortization of debt discounts, premiums and issuance costs | 770 | 830 |
Other non-cash items | (987) | 273 |
Changes in assets and liabilities: | ||
Accounts receivable, net | (2,991) | 1,063 |
Inventories, net | (4,914) | (8,470) |
Prepaid expenses and other assets | 960 | 33 |
Accounts payable | 1,618 | (2,776) |
Accrued compensation and related benefits | 3,018 | 4,113 |
Deferred revenue | 884 | (3,467) |
Other liabilities | 3,212 | (5,978) |
Net cash used in operating activities | (43,287) | (89,370) |
Investing activities | ||
Purchases of short-term investments | (94,896) | (137,302) |
Proceeds from sales and maturities of investments | 117,964 | 53,000 |
Purchases of property and equipment | (2,831) | (3,825) |
Net cash provided by (used in) investing activities | 20,237 | (88,127) |
Financing activities | ||
Proceeds from bridge loans | 0 | 25,000 |
Proceeds from issuance of Series B Preferred Stock | 0 | 225,000 |
Repayment of term loan and advances under revolving credit facility | (2,083) | (6,838) |
Payment of debt and equity issuance costs | 0 | (12,547) |
Repurchase of common stock | (5,414) | (563) |
Proceeds from ESPP stock issuance and exercise of stock options | 827 | 917 |
Payments for taxes related to net share settlement of equity awards and other | (139) | (211) |
Net cash provided by (used in) financing activities | (6,809) | 230,758 |
Effect of foreign exchange rate fluctuations on cash and cash equivalents | 34 | (404) |
Net increase (decrease) in cash, cash equivalents and restricted cash | (29,825) | 52,857 |
Cash, cash equivalents and restricted cash at beginning of period | 82,324 | 29,467 |
Cash, cash equivalents and restricted cash at end of period | 52,499 | 82,324 |
Supplemental disclosures of cash flow information | ||
Cash paid for interest | 3,819 | 3,493 |
Cash paid for income taxes, net of refunds | 801 | 309 |
Non-cash right-of-use assets and lease liabilities | 629 | 651 |
Asset retirement obligations | $ 758 | $ 718 |
Description of Business
Description of Business | 12 Months Ended |
Dec. 31, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Description of Business | 1. Description of Business Standard BioTools Inc. (Standard BioTools or the Company), formerly known as Fluidigm Corporation, is a Delaware corporation headquartered in South San Francisco, California. The Company has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the Company endeavors to provide reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies that help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. On January 5, 2024, the Company completed its previously announced merger (the Merger) with SomaLogic, Inc. (SomaLogic) a protein biomarker discovery company enabling researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. See Note 16 – Subsequent Events, for more information. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2023 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | 2. Summary of Significant Accounting Policies Basis of Presentation and Consolidation The accompanying consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (U.S. GAAP) and include the accounts of the Company's wholly owned subsidiaries. As of December 31, 2023 , the Company had wholly owned subsidiaries in Singapore, Canada, the Netherlands, Japan, France, Italy, the United Kingdom, China, Germany and Norway. All subsidiaries, except for Singapore, use their local currency as their functional currency. The Singapore subsidiary uses the U.S. dollar as its functional currency. All intercompany transactions and balances have been eliminated in consolidation. Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates on historical experience, the current economic environment and on various other assumptions believed to be reasonable, which together form the basis for making judgments about the carrying values of assets and liabilities. These accounting matters included but were not limited to inventory and related reserves, the carrying value of goodwill and other long-lived assets, and the potential outcome of uncertain tax positions that have been recognized in the Company's financial statements or tax returns. The Company also uses significant judgment in determining the fair value of financial instruments, including debt and equity instruments. Actual results could differ materially from these estimates and could have a material adverse effect on the Company's consolidated financial statements. Foreign Currency Assets and liabilities of non-U.S. subsidiaries that use their local currency as their functional currency are translated into U.S. dollars at exchange rates in effect on the balance sheet date. Income and expense accounts are translated at monthly average exchange rates during the year. The adjustments resulting from the foreign currency translations are recorded in accumulated other comprehensive loss, a separate component of stockholders’ equity (deficit). Revenue Recognition The Company generates revenue primarily from the sale of its products and services. Product revenue is derived from the sale of instruments and consumables, including IFCs, assays and reagents. Service revenue is derived from the sale of instrument service contracts, repairs, installation, training and other specialized product support services. The Company also generates revenue from product development agreements, license and royalty agreements, and grants. Revenue is reported net of any sales, use and value-added taxes the Company collects from customers as required by government authorities. Research and development cost includes costs associated with development and grant revenue. The Company recognizes revenue based on the amount of consideration it expects to receive in exchange for the goods and services it transfers to the customer. The Company's commercial arrangements typically include multiple distinct products and services, and the Company allocates revenue to these performance obligations based on their relative standalone selling prices. Standalone selling prices (SSP) are generally determined using observable data from recent transactions. In cases where sufficient data is not available, the Company estimates a product’s SSP using a cost plus a margin approach or by applying a discount to the product’s list price. Product Revenue The Company recognizes product revenue at the point in time when control of the goods passes to the customer, and the Company has an enforceable right to payment. This generally occurs either when the product is shipped from one of the Company's facilities or when it arrives at the customer’s facility, based on the contractual terms. Customers do not have a unilateral right to return products after delivery. Invoices are generally issued at shipment or in advance of service and become due in 30 to 60 days. The Company sometimes perform shipping and handling activities after control of the product passes to the customer. The Company has made an accounting policy election to account for these activities as product fulfillment activities rather than as separate performance obligations. Service and Other Revenue The Company recognizes revenue from repairs, maintenance, installation, training and other specialized product support services at the point in time the work is completed. Installation and training services are generally billed in advance of service. Repairs and other services are generally billed at the point the work is completed. Revenue associated with instrument service contracts is recognized on a straight-line basis over the life of the agreement, which is generally one to three years . The Company believes this time-elapsed approach is appropriate for service contracts because the Company provides services on demand throughout the term of the agreement. Invoices are generally issued in advance of service on a monthly, quarterly, annual or multi-year basis. Payments made in advance of service are reported on the Company's consolidated balance sheet as deferred revenue. Other revenue consists of license and royalty revenue and grant revenue. The Company recognizes revenue from license agreements when the license is transferred to the customer and the customer is able to use and benefit from the license. For contracts that include sales-based royalties, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied. The Company receives grants from various entities to perform research and development activities over contractually defined periods. Grant revenue is not accounted for under ASC Topic 606, Revenue from Contracts with Customers , as the grant agreement is not with a customer. As there is no authoritative U.S. GAAP guidance for grants awarded to for-profit entities, the Company has applied the guidance in ASC Topic 958, Not-for-Profit Entities by analogy. Revenue is generally recognized provided that the conditions under which the grants were provided have been met and any remaining performance obligations are perfunctory. Significant Judgments Applying the revenue recognition practices discussed above often requires significant judgment. Significant judgment is required when interpreting commercial terms in sales agreements and determining when control of goods and services passes to the customer. Judgment is also required when identifying performance obligations, estimating SSP and allocating purchase consideration in agreements that include multiple performance obligations. Any material changes created by errors in judgment could have a material effect on the Company's operating results and overall financial condition. Cash and Cash Equivalents The Company considers all highly liquid financial instruments with maturities at the time of purchase of three months or less to be cash equivalents. Cash and cash equivalents balance at December 31, 2023, and 2022 represent cash on deposit with banks and money market funds. Short-term Investments Short-term investments are comprised of U.S treasury securities that mature within one year. The Company classifies its short-term investments as available-for-sale and records such assets at estimated fair value in the consolidated balance sheets. Any unrealized gains and losses from short-term investments are reported as a component of other comprehensive income (loss) within the consolidated statements of comprehensive loss and as a separate component of stockholders’ equity (deficit). The Company evaluates its short-term investments to assess whether investments with unrealized loss positions are other-than-temporarily impaired. An investment is considered to be other-than-temporarily impaired if the impairment is related to deterioration in credit risk or if it is likely that the Company will sell the securities before the recovery of their cost basis. No investment has been assessed as other than temporarily impaired. Realized gains and losses are calculated on the specific identification method and are recorded as interest income (loss). There were no realized gains and losses from sales of short-term investments during any of the periods presented. The Company excludes accrued interest from the fair value and amortized cost basis of its short-term investments. Accounts Receivable, net Trade accounts receivable are recorded at net invoice value. The Company reviews its exposure to accounts receivable and provides allowances of specific amounts if collectability is no longer reasonably assured based on historical experience and specific customer collection issues. The Company evaluates such allowances on a regular basis and adjust them as needed. Concentrations of Business and Credit Risk Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents, short-term investments, and accounts receivable. The Company's cash, cash equivalents, and short-term investments may consist of deposits held with banks, money market funds, and other highly liquid investments that may at times exceed federally insured limits. Cash equivalents and short-term investments are financial instruments that potentially subject the Company to concentrations of risk. Under the Company's investment policy, the Company invests exclusively in securities issued by the U.S. government or U.S. government agencies, or in government money-market funds. The goals of the Company's investment policy, in order of priority, are to: preserve capital, meet liquidity needs, and optimize returns. For these reasons, management believes that the Company is not exposed to significant credit risk. The Company generally does not require collateral to support credit sales. To reduce credit risk, the Company performs credit evaluations of its customers. The Company's products include components that are currently procured from a single source or a limited number of sources. The Company believes that other vendors would be able to provide similar components; however, the qualification of such vendors may require start-up time. In order to mitigate any adverse impacts from a disruption of supply, the Company attempts to maintain an adequate supply of critical limited-source components. Inventories, net Inventories are stated at the lower of cost (on a first-in, first-out basis) or net realizable value. Inventory costs include direct materials, direct labor, and normal manufacturing overhead. The Company regularly reviews inventory for excess and obsolete products and components. Significant judgment is required in determining provisions for slow-moving, excess, and obsolete inventories which are recorded when required to reduce inventory values to their estimated net realizable values based on product life cycle, development plans, product expiration, discontinuance of product lines, and quality issues. Property and Equipment, net Property and equipment, including leasehold improvements, are stated at cost less accumulated depreciation. Accumulated depreciation is calculated using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the estimated useful lives of the assets or the remaining term of the lease, whichever is shorter. The estimated useful lives of the Company's property and equipment are generally as follows: computer equipment and software, three to four years ; laboratory and manufacturing equipment, two to seven years ; and office furniture and fixtures, five years . Leases At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. Lease terms are determined at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. For its long-term operating leases, the Company recognizes a lease liability and a right-of-use asset (ROU) on its consolidated balance sheets. ROU assets represent the Company's right-to-use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. The lease liability is determined at the lease commencement date based on the present value of lease payments over the lease term. As most of the Company's leases do not provide an implicit rate, the Company generally uses its incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a term similar to the lease arrangement. Significant judgment is required in determining the incremental collateralized borrowing rate. The ROU asset is based on the lease liability, adjusted for any prepaid or deferred rent. Lease expense is recognized on a straight-line basis over the lease term. Sublease income from an operating lease is recognized on a straight-line basis over the sublease term. The Company does not have any finance leases. The Company elected the short-term lease recognition exemption for all leases that qualify. For those leases that qualify, the Company will not recognize ROU assets or lease liabilities for leases with an initial lease term of one year or less. The Company also elected not to separate lease and nonlease components for the Company's building leases. The nonlease components are generally variable in nature and are expected to represent most of the Company's variable lease costs. Variable costs are expensed as incurred. The Company has taken a portfolio approach for its vehicle leases by country. Business Combinations, Goodwill, Intangible Assets and Other Long-Lived Assets The Company has completed acquisitions of businesses in the past and may acquire additional businesses or technologies in the future. The results of businesses acquired in a business combination are included in the Company's consolidated financial statements from the date of acquisition. The Company allocates the purchase price, which is the sum of the consideration provided in a business combination, to the identifiable assets and liabilities of the acquired business at their acquisition date fair values. Determining the fair value of assets acquired and liabilities assumed requires management to use significant judgment and estimates, including the selection of valuation methodologies and estimates of future revenue. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. The Company's intangible assets include developed technology, patents and licenses. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets’ respective estimated useful lives. Judgment is needed to assess the factors that could indicate an impairment of intangible assets. Goodwill and intangible assets with indefinite lives are not subject to amortization but are tested for impairment on an annual basis during the fourth quarter or whenever events or changes in circumstances indicate the carrying amount of these assets may not be recoverable. Events or changes in circumstances that could affect the likelihood that the Company will be required to recognize an impairment charge include, but are not limited to, declines in the Company's stock price or market capitalization, economic downturns and other macroeconomic events, declines in the Company's market share or revenues, or significant litigation. Any impairment charges could have a material adverse effect on the Company's operating results and net asset value in the period in which the Company recognizes the impairment charge. In evaluating goodwill and intangible assets with indefinite lives for indications of impairment, the Company first conducts an assessment of qualitative factors to determine whether it is more likely than not that the fair value of each of the Company's reporting units is less than its carrying amount. If the Company determines that it is more likely than not that the fair value of each of its reporting units is less than its carrying amount, the Company compares the fair value of each of its reporting units to its carrying value. If the fair value of each of the Company's reporting units exceeds its carrying value, goodwill is not considered impaired, and no further analysis is required. If the carrying value of each of the Company's reporting units exceeds its fair value, then an impairment loss equal to the difference would be recorded to goodwill. The Company evaluates its long-lived assets, including finite-lived intangibles, for indicators of possible impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If any indicator of impairment exists, the Company assesses the recoverability of the affected long-lived assets by determining whether the carrying value of the asset can be recovered through undiscounted future operating cash flows. If impairment is indicated, the Company estimates the asset’s fair value using future discounted cash flows associated with the use of the asset and adjust the carrying value of the asset accordingly. Series B Redeemable Preferred Stock The Purchase Agreements (as described in Note 9) for the issuance of shares of Series B Redeemable Preferred Stock were accounted for as forward sales contracts at fair value in accordance with ASC Topic 480, Distinguishing Liabilities from Equities . The Series B Redeemable Preferred Stock was classified as mezzanine equity and recorded at fair value upon issuance, net of issuance costs, due to its redemption features that are outside of the Company’s control. Mezzanine equity is presented separately on the consolidated balance sheets between liabilities and shareholders’ equity because it shares characteristics of both. In the year ended December 31, 2022, the Company recognized a $ 60.1 million loss on the forward sales of Series B Preferred Stock and a $ 13.7 million loss on the Bridge Loans due to the increase in the price of the Company's common stock from January 23, 2022 (the date of the Purchase Agreements and the Bridge Loan agreements) to the Private Placement Closing Date. See Note 9 for additional information. Restructuring and Related Charges The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. Costs for involuntary separation programs are recorded when management has approved the plan for separation, the employees are identified and made aware of the benefits they are entitled to, it is unlikely that the plan will change significantly, and if applicable, any required governmental notification is made. Costs associated with benefits that are contingent on the employee continuing to provide service are recognized over the required service period. Costs associated with leased facilities (net of sublease income, if applicable) that the Company has vacated as part of a restructuring plan are also included. Transaction-related Expenses The Company expensed certain costs incurred related to the merger agreement with SomaLogic, described further in Note 16, including legal, advisory, accounting and other transaction-related costs. The expenses in the prior period relate to the private placement whereby the Company issued and sold an aggregate of $ 225.0 million of convertible preferred stock in connection with the conversion of the bridge loans, which closed on April 4, 2022. Deferred Grant Income Proceeds from the NIH Contract have been principally recorded as capital expenditures and to offset applicable operating costs. The non-operating income recognized from the grant proceeds received in excess of the amounts spent for capital expenditures and operating expenses is reflected on the consolidated statement of operations as surplus funding from the NIH contract. The NIH Contract met the definition of grants related to assets as the primary purpose for the payments was to fund the purchase and construction of capital assets to scale up production capacity. The Company elected to record the grants received as deferred income in accordance with International Accounting Standards (IAS) 20. Deferred grant income related to production capacity expansion is being amortized for the related assets as a reduction of depreciation expense. Term Loan, net The term loan is recorded at its carrying value, which includes the outstanding principal amount and the cumulative accreted final payment, less unamortized debt issuance costs. Amortization of the debt issuance costs and accretion of the final payment are reflected in interest expense. The final payment is being accreted to the carrying value of the term loan through the expected maturity of July 1, 2025 using the effective interest method. Debt issuance costs were recorded as an offset to the carrying value of the loan and are amortized over the expected term also using the effective interest method. Convertible Notes, net The Company records the 2014 Notes and 2019 Notes (as described in Note 6) at their carrying values, which includes their principal amounts plus accrued and unpaid interest. Offering-related costs, including underwriting costs, on the 2014 Notes and 2019 Notes were capitalized as debt issuance costs, recorded as an offset to the carrying value of the related Notes, and are amortized over the expected term of the related Notes using the effective interest method. Treasury Stock The Company uses the cost method to account for the repurchases of its common stock in accordance with ASC 505-30, Equity-Treasury Stock. The direct costs associated with settled share repurchases, including trading commissions, are reported as treasury stock in the shareholders’ equity (deficit) section of the Company's consolidated balance sheets. Fair Value of Financial Instruments The Company's financial instruments consist primarily of cash and cash equivalents, restricted cash, short-term investments, accounts receivable, accounts payable, term loan and convertible notes. The Company's cash equivalents, restricted cash, accounts receivable and accounts payable generally have short maturity or payment periods. Accordingly, their carrying values approximated their fair values at December 31, 2023 and 2022. The Company's short-term investments consist of U.S. treasury securities that are classified as available-for-sale and reported at fair value on the Company's consolidated balance sheets. The convertible notes and term loan are presented at their net carrying values. As a basis for computing fair value, the Company follows a three-tier value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level I: observable inputs such as quoted prices in active markets; Level II: inputs other than quoted prices in active markets that are observable either directly or indirectly; and Level III: unobservable inputs for which there is little or no market data, which requires the Company to develop its own assumptions. This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. The Company's cash equivalents, which include money market funds are classified as Level I because they are valued using quoted market prices. The Company's short-term investments, which include U.S. treasuries, are classified as Level II because they are valued using non-binding market consensus prices that were corroborated with observable market data, quoted market prices for similar instruments, or pricing models. The Company's convertible notes are not regularly traded, and it is difficult to estimate a reliable and accurate market price for these securities. The estimated fair values of these securities represent Level III valuations since a fair value for these securities cannot be determined by using readily observable inputs or measures, such as market prices. Fair values were estimated using pricing models and risk-adjusted value ranges. The estimated fair value of the Company's term loan also represents a Level III valuation since the value cannot be determined by using readily observable inputs or measures, such as market prices. The fair value of the Company's term loan was estimated using a discounted cash flows approach and current market interest rate data for similar loans. The carrying value of the Company's lines of term loan approximates fair value as the interest rate and terms are reflective of the rate the Company could obtain on debt with similar terms and conditions. Research and Development The Company recognizes research and development expenses in the period incurred. Research and development (R&D) expenses generally consist of personnel costs, independent contractor costs, prototype and materials expenses, allocated facilities and information technology expenses, and related overhead expenses. Advertising Costs The Company expenses advertising costs as incurred. The Company incurred advertising costs of $ 2.0 million and $ 3.9 million during the years ended December 31, 2023 and 2022 , respectively. Stock-Based Compensation The Company recognizes compensation costs for all stock-based awards, including stock options, Restricted Share Units (RSUs), Performance Share Units (PSUs) and stock purchased under the Company's Employee Share Purchase Plan (ESPP), based on the grant date fair value of the award. The Company recognizes stock-based compensation expense on a straight-line basis over the requisite service periods for non-performance-based awards. For RSUs, fair value is measured based on the closing fair market value of the Company's common stock on the date of grant. For PSUs with a market condition, the Company uses a Monte Carlo simulation pricing model to incorporate the market condition effects at the grant date. The Monte Carlo pricing model requires inputs which are subjective and generally requires judgment. For PSUs with performance conditions, stock-based compensation expense is recognized over the requisite service period when the achievement of each individual performance goal becomes probable. The fair value of options and stock purchases under ESPP on the grant date is estimated using the Black-Scholes option-pricing model, which requires the use of certain subjective assumptions, including expected term, volatility, risk-free interest rate and the fair value of the Company's common stock. These assumptions generally require judgment. The Company determines the expected volatility based on the Company's historical stock price volatility generally commensurate with the estimated expected term of the stock awards. The expected term of an award is based on historical forfeiture experience, exercise activity, and the terms and conditions of the stock awards. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities approximately equal to each grant’s expected term. The Company accounts for forfeitures as they occur. Income Taxes The Company uses the asset and liability method to account for income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Valuation allowances are provided when the expected realization of deferred tax assets does not meet a “more likely than not” criterion. The Company makes estimates and judgments about its future taxable income that are based on assumptions that are consistent with its plans and estimates. Should the actual amounts differ from the Company's estimates, the amount of the valuation allowance could be materially impacted. Changes in these estimates may result in significant increases or decreases to the Company's tax provision in a period in which such estimates are changed, which in turn would affect net income or loss. The Company recognizes the financial statement effects of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. Any interest and penalties related to uncertain tax positions are reflected in the income tax provision. Segment Reporting The Company operates in two reportable segments: proteomics and genomics. Each segment is identified by its unique portfolio of products. Proteomics includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. Genomics includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. The Company's CEO, who is its Chief Operating Decision Maker (CODM), measures segment performance using gross profit which is determined by subtracting cost of product and service revenues from segment revenues. Depreciation and amortization expense is included in each segment’s gross profit. Comprehensive Loss Comprehensive loss is comprised of net loss and other comprehensive income (loss). Other comprehensive income (loss) consists of unrealized gains and losses on the Company's short-term investments and foreign currency translation adjustments. Total comprehensive loss for all periods presented has been disclosed in the consolidated statements of comprehensive loss. Net Loss per Share The Company's basic and diluted net loss per share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding for the period. RSUs, PSUs, stock options to purchase the Company's common stock, ESPP shares pending issuance, Series B Preferred Stock and convertible notes are considered to be potentially dilutive common shares but have been excluded from the calculation of diluted net loss per share as their effect is anti-dilutive for all periods presented. The following potentially dilutive common shares were excluded from the computations of diluted net loss per share for the periods presented because including them would have been anti-dilutive (in thousands): Year Ended December 31, 2023 2022 RSUs, PSUs, stock options and ESPP shares 16,740 15,752 Series B Preferred Stock 75,164 75,164 2019 Notes (1) 18,966 18,966 2014 Notes 10 10 Total 110,880 109,892 (1) The conversion rate is subject to adjustment upon the occurrence of certain specified events, including voluntary conversion of the 2019 Notes (as defined below) prior to the Company’s exercise of the Issuer’s Conversion Option (as defined in the 2019 Notes) or in connection with a make-whole fundamental change, entitling the holders, under certain circumstances, to a make-whole premium in the form of an increase in the conversion rate determined based on the effective date and current price of the Company’s common stock, subject to a minimum and maximum price per share. The maximum number of additional shares of common stock that may be issued under the make-whole premium is 4,741,374 shares. Refer to Note 6 for additional information on the 2019 Notes. The 2,709,703 common shares that were repurchased during the year ended December 31, 2023 have also been excluded from the Company's earnings per share and diluted earnings per share calculations. Recent Accounting Changes and Accounting Pronouncements Adoption of New Accounting Guidance From time to time, new accounting standards are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position or results of operations upon adoption. Recent Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07, Segmen |
Revenue and Geographic Area
Revenue and Geographic Area | 12 Months Ended |
Dec. 31, 2023 | |
Revenue from Contract with Customer [Abstract] | |
Revenue and Geographic Area | 3. Revenue and Geographic Area Disaggregation of Revenue by Product Type and Geographic Area The following tables present the Company's revenue for the years ended December 31, 2023 and 2022, respectively, based on product type and the geographic location of customers’ facilities (in thousands): Year Ended December 31, 2023 2022 Instruments $ 37,459 $ 25,664 Consumables 41,739 46,790 Total product revenue 79,198 72,454 Service revenue 25,980 23,712 Product and service revenue 105,178 96,166 Other revenue 1,162 1,782 Total revenue $ 106,340 $ 97,948 Year Ended December 31, 2023 2022 Americas $ 46,196 $ 43,982 Europe, Middle East and Africa (EMEA) 36,201 33,136 Asia-Pacific 23,943 20,830 Total revenue $ 106,340 $ 97,948 Most of the Company's principal operations, other than manufacturing, are located at its corporate headquarters in the United States. Revenue from customers in the United States represented $ 44.1 million, or 42 %, of total revenues for the year ended December 31, 2023 , and $ 41.0 million, or 42 %, of total revenues for the year ended December 31, 2022. Refer to Note 13 for additional information on revenue by reporting segment. Revenue from customers in China represented $ 15.8 million, or 15 %, of total revenues for the year ended December 31, 2023 , and 11 % of total revenues for the year ended December 31, 2022. With the exception of China in 2023 and 2022, no foreign country or jurisdiction had revenue in excess of 10% of the Company's total revenue during the years ended December 31, 2023 and 2022. One genomics customer accounted for 10 % and 11 % of the Company's total revenue for the years ended December 31, 2023 and 2022 , respectively, and 14 % and 16 % of outstanding net trade receivables at December 31, 2023 and 2022, respectively. No other customer represented more than 10% of the Company's total revenue for the fiscal years ended December 31, 2023 and 2022 . Revenue from the Company's five largest customers represented 24 % of total revenue for the year ended December 31, 2023 and 19 % of total revenue the year ended December 31, 2022. Long-lived Assets by Geographical Area The Company had long-lived assets consisting of property and equipment, net of accumulated depreciation, and operating lease ROU assets, net of accumulated amortization, in the following geographic areas for each year presented (in thousands): December 31, 2023 2022 United States $ 29,646 $ 31,785 Singapore 17,097 21,178 Canada 6,231 5,394 Other Asia-Pacific 889 875 EMEA 987 303 Total $ 54,850 $ 59,535 Unfulfilled Performance Obligations The consolidated balance sheets as of December 31, 2023 and 2022 included total deferred revenue of $ 15.1 million and $ 14.6 million , respectively. During the year ended December 31, 2023 , $ 10.6 million of the opening deferred revenue balance was recognized as revenue and $ 11.1 million of net additional advance payments, primarily for instrument service contracts, were received from customers. The Company expects to recognize revenue from unfulfilled performance obligations associated with service contracts that were partially completed as of December 31, 2023 in the following periods (in thousands): Fiscal Year Expected Revenue (1) 2024 13,253 2025 6,634 2026 3,061 Thereafter 1,112 Total $ 24,060 (1) Expected revenue includes both billed amounts included in deferred revenue and unbilled amounts that are not reflected in the Company's consolidated financial statements and are subject to change if the Company's customers decide to cancel or modify their contracts. Purchase orders for instrument service contracts can generally be canceled without penalty before the service period begins. The Company also has unsatisfied performance obligations for service contracts with an expected term of one year or less not included in the amounts above. |
Goodwill and Intangible Assets,
Goodwill and Intangible Assets, net | 12 Months Ended |
Dec. 31, 2023 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Goodwill and Intangible Assets, net | 4. Goodwill and Intangible Assets, net During the second quarter of 2022, the Company discontinued the sale of products that utilized the developed technology acquired from InstruNor and recorded a $ 3.5 million impairment charge to write-off the unamortized portion of the related intangible asset. The Company assessed goodwill for impairment when it performed its annual testing at the end of the fourth quarter of 2023. A qualitative approach was employed which included assessing significant events and circumstances such as the Company's current results, assumptions regarding future performance, strategic initiatives and overall macroeconomic factors to determine the existence of potential indicators of impairment and assess if it is more likely than not that the fair value of each of the Company's reporting units is less than their carrying value. The Company determined there was no impairment as of December 31, 2023. The changes in the carrying value of goodwill by segment are as follows (in thousands): Proteomics Genomics Total Balance as of December 31, 2022 $ 85,752 $ 20,499 $ 106,251 Foreign currency translation 46 20 66 Balance as of December 31, 2023 $ 85,798 $ 20,519 $ 106,317 Intangible assets with finite lives include developed technology, patents and licenses. In the consolidated balance sheets, developed technology is reported separately while patents and licenses are reported in other non-current assets. Intangible assets, net, were as follows (in thousands): December 31, 2023 Gross Amount Accumulated Net Weighted- Developed technology $ 117,354 $ ( 115,954 ) $ 1,400 10.0 years Patents and licenses $ 11,250 $ ( 11,243 ) $ 7 7.0 years December 31, 2022 Gross Amount Accumulated Net Weighted- Developed technology $ 117,194 $ ( 104,594 ) $ 12,600 10.0 years Patents and licenses $ 11,247 $ ( 10,669 ) $ 578 7.0 years Total amortization expense of the Company's intangible assets was $ 11.8 million and $ 12.2 million for the years ended December 31, 2023 and 2022 , respectively. The $ 3.5 million impairment charge for the InstruNor developed technology intangible asset was recorded in research and development expense in 2022 and it is reflected in accumulated amortization in the above table. Based on the net carrying value of intangible assets at December 31, 2023, the Company expects annual amortization expense to be as follows (in thousands): Fiscal Year Developed Patents and Total 2024 1,400 7 1,407 Total $ 1,400 $ 7 $ 1,407 |
Balance Sheet Details
Balance Sheet Details | 12 Months Ended |
Dec. 31, 2023 | |
Balance Sheet Related Disclosures [Abstract] | |
Balance Sheet Details | 5. Balance Sheet Details Cash, Cash Equivalents and Restricted Cash Cash, cash equivalents and restricted cash consisted of the following (in thousands): December 31, 2023 December 31, 2022 Cash and cash equivalents $ 51,704 $ 81,309 Restricted cash 795 1,015 Total cash, cash equivalents and restricted cash $ 52,499 $ 82,324 Restricted cash of $ 0.8 and $ 1.0 million is included in other non-current assets on the consolidated balance sheets as of December 31, 2023 and 2022, respectively. Inventories, net Inventories, net consisted of the following (in thousands): December 31, 2023 December 31, 2022 Raw materials $ 15,539 $ 16,866 Work-in-process 282 945 Finished goods 11,753 15,245 Total inventory, gross 27,574 33,056 Allowance for excess and obsolete inventory ( 7,041 ) ( 11,583 ) Total inventories, net $ 20,533 $ 21,473 Property and Equipment, net Property and equipment, net consisted of the following (in thousands): December 31, 2023 December 31, 2022 Laboratory and manufacturing equipment $ 35,563 $ 33,329 Leasehold improvements 13,785 12,234 Computer equipment and software 6,232 5,793 Office furniture and fixtures 1,762 1,713 Property and equipment, gross 57,342 53,069 Less accumulated depreciation and amortization ( 35,489 ) ( 29,029 ) Construction-in-progress 2,334 1,612 Property and equipment, net $ 24,187 $ 25,652 Depreciation expense was $ 3.4 million and $ 2.8 million for the years ended December 31, 2023 and 2022, respectively. Accrued Compensation and Related Benefits Accrued compensation and related benefits, which are included in current liabilities on the consolidated balance sheets consisted of the following (in thousands): December 31, 2023 December 31, 2022 Accrued incentive compensation $ 7,337 $ 1,170 Accrued vacation 2,711 2,795 Accrued payroll taxes and other 994 1,174 Accrued restructuring 825 4,014 Accrued compensation and related benefits $ 11,867 $ 9,153 Refer to Note 14 for additional information on restructuring. Other Accrued Liabilities Other accrued liabilities, which are included in current liabilities on the consolidated balance sheets consisted of the following (in thousands): December 31, 2023 December 31, 2022 Accrued commissions $ 1,010 $ 800 Accrued interest 295 318 Accrued legal expenses 964 349 Accrued taxes 1,230 1,443 Uninvoiced receipts 1,516 1,078 Accrued warranties 2,593 678 Customer advances 447 577 Accrued restructuring — 19 Accrued other 1,097 913 Other accrued liabilities $ 9,152 $ 6,175 Deferred Grant Income In September 2020, the Company executed a contract with the National Institutes of Health (NIH) under NIH’s Rapid Acceleration of Diagnostics program to support the expansion of the Company’s production capacity for its COVID-19 test products. Under the now-completed contract, the Company received $ 34.0 million of funding from the NIH and used $ 22.2 million on capital expenditures for their Singapore manufacturing facility. The amortization of the deferred income, which is offset against depreciation, was $ 3.6 million and $ 3.5 million for the years ended December 31, 2023 and 2022, respectively . Cumulative amounts amortized and offsetting against depreciation expense for these assets placed in service were $ 7.8 million and $ 4.2 million as of December 31, 2023 and 2022 , respectively, and the carrying values of these assets were $ 14.4 million and $ 18.0 million, respectively, as of these same dates. The current portion of deferred grant income on the Company’s consolidated balance sheets represents amounts expected to be offset against depreciation expense over the next twelve months. The non-current portion of deferred grant income includes amounts expected to be offset against depreciation expense in later periods. |
Debt
Debt | 12 Months Ended |
Dec. 31, 2023 | |
Debt Disclosure [Abstract] | |
Debt | 6. Debt The carrying value of debt consists of the following (in thousands): December 31, 2023 December 31, 2022 Convertible notes: 2014 Notes $ 569 $ 568 2019 Notes, non-current — 54,047 2019 Notes, current 54,530 — Total convertible notes, net 55,099 54,615 Term loan, non-current 3,414 8,194 Term loan, current 5,000 2,083 Total debt $ 63,513 $ 64,892 Convertible Notes In February 2014, the Company closed an underwritten public offering of 2014 Senior Convertible Notes (2014 Notes), which will mature on February 1, 2034, unless earlier converted, redeemed or repurchased in accordance with the terms of the 2014 Notes. Holders may require the Company to repurchase all or a portion of their 2014 Notes on each of February 6, 2024 and February 6, 2029, at a repurchase price in cash equal to 100 % of the principal amount of the 2014 Notes plus accrued and unpaid interest. On February 6, 2024, one holder of the 2014 Notes exercised their repurchase right, and the Company repurchased an immaterial amount of principal and accrued interest. In November 2019, the Company issued $ 55.0 million aggregate principal amount of 2019 Senior Convertible Notes (2019 Notes). Net proceeds from the 2019 Notes issuance of $ 52.7 million, after deductions for commissions and other debt issuance costs, were used to retire all but $ 1.1 million of the aggregate principal value of the 2014 Notes then outstanding. The 2019 Notes bear interest at 5.25 % per annum, payable semiannually on June 1 and December 1 of each year. The 2019 Notes will mature on December 1, 2024, unless earlier repurchased or converted pursuant to their terms. The 2019 Notes will be convertible at the option of the holder at any point prior to the close of business on the second scheduled trading day preceding the maturity date. The initial conversion rate of the 2019 Notes is 344.8276 shares of the Company’s common stock per $ 1,000 principal amount of 2019 Notes (which is equivalent to an initial conversion price of approximately $ 2.90 per share). The conversion rate is subject to adjustment upon the occurrence of certain specified events. Those certain specified events include voluntary conversion of the 2019 Notes prior to the Company’s exercise of the Issuer’s Conversion Option (as defined therein) or in connection with a make-whole fundamental change, entitling the holders, under certain circumstances, to a make-whole premium in the form of an increase in the conversion rate determined by reference to a make-whole table set forth in the indenture governing the 2019 Notes. The conversion rate will not be adjusted for any accrued and unpaid interest. The 2019 Notes are convertible at the Company’s option in whole but not in part into shares of the Company’s common stock upon certain conditions if the volume-weighted average price of the Company’s common stock has equaled or exceeded 130 % of the conversion price then in effect for a specified number of days. Offering-related costs related to both notes were capitalized as debt issuance costs and are recorded as an offset to the carrying value of the 2019 Notes. Revolving Credit Facility On August 2, 2018, the Company entered into a revolving credit facility with Silicon Valley Bank (as amended, the Revolving Credit Facility) in an aggregate principal amount of up to the lesser of (i) $ 15.0 million or (ii) the sum of (a) 85 % of eligible receivables and (b) 50 % of eligible inventory, in each case, subject to certain limitations (Borrowing Base), provided that the amount of eligible inventory that may be counted towards the Borrowing Base shall be subject to a cap as set forth in the Revolving Credit Facility. The Revolving Credit Facility was collateralized by substantially all the Company’s property, other than intellectual property and contained certain financial covenants. There were no borrowings under the Revolving Credit Facility and it expired on August 2, 2023. Term Loan Facility, net On August 2, 2021, the Company amended its Revolving Credit Facility to, amongst other things, provide for a new $ 10.0 million term loan facility (the Term Loan Facility). As of December 31, 2023, the Term Loan Facility was fully drawn with an outstanding principal balance of $ 7.9 million and a carrying value of $ 8.4 million . The interest rate on the Term Loan Facility is the greater of 4.0 % per annum or a floating per annum rate equal to the prime rate plus 0.75 %. Interest on any outstanding term loan advances is due and payable monthly. In addition to the monthly interest payments, a final payment equal to 6.5 % of the original principal amount of each advance is due the earlier of the maturity date or the date the advance is repaid. Principal balances are required to be repaid in 24 equal installments which began on August 1, 2023. The stated maturity of the Term Loan Facility is July 1, 2025. However, if the principal amount of the Company’s convertible debt exceeds $ 0.6 million as of June 1, 2024 or if the maturity date of the 2019 Notes has not been extended beyond January 1, 2026 by June 1, 2024, then the maturity date of the Term Loan Facility will be June 1, 2024. As there were no contractual requirement to repay the loan as of the balance sheet date, $ 3.4 million of the Term Loan Facility's carrying value is classified as non-current, consistent with its terms, on the Company’s balance sheet as of December 31, 2023. On October 26, 2023, the Company entered into an amendment to the Term Loan Facility agreement which removed certain collateral covenants related to the Revolving Credit Facility due to its expiration on August 2, 2023. Future minimum payments under the Term Loan Facility including the end of term fee payment as of December 31, 2023, are as follows (in thousands): 2024 $ 5,000 2025 2,917 7,917 End of term fee and debt issuance costs 497 Total Term Loan Facility $ 8,414 Bridge Loans On January 23, 2022, the Company entered into separate loan agreements (collectively, the Bridge Loan Agreements) with various investors for a $ 25.0 million term loan (collectively, the Bridge Loans). The Bridge Loans were fully drawn on January 24, 2022, and automatically converted into Series B Preferred Stock upon the subsequent closing of the Private Placement (as defined below) on April 4, 2022 (the Private Placement Closing Date). Applying the guidance in ASC 825 Financial Instruments, the Company elected to record the Bridge Loans at their fair value using a probability‐weighted expected return method for the valuation analysis of the Bridge Loans. This resulted in a $ 13.7 million change in fair value of the Bridge Loans from $ 25.0 million at inception to $ 38.7 million as of the Private Placement Closing Date, including the portion attributable to accrued interest, which is reflected as a non-operating unrealized loss on the Bridge Loans in the accompanying consolidated statements of operations for the year ended December 31, 2022. See Note 9 for further detail. |
Commitments and Contingencies
Commitments and Contingencies | 12 Months Ended |
Dec. 31, 2023 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | 7. Commitments and Contingencies Leases The Company has operating leases for buildings, equipment and vehicles. Existing leases have remaining terms ranging from less than one year to approximately 6 years . Some leases contain options to extend the lease, usually for up to five years , along with termination options. The Company’s facility lease has an expiration date of April 30, 2030 and contains an option to extend the lease , for up to five years , along with termination options . The Company is utilizing one floor (19 th floor) for its corporate operations with all expense for this floor included within selling, general and administrative expense on the Company’s consolidated statement of operations for the years ended December 31, 2023 and 2022. As part of the Company’s restructuring plan discussed further in Note 14, in August 2022, the Company entered into an agreement to sublease approximately 25 % of its corporate headquarters space (18 th floor) in South San Francisco, California for a period of 39 months. As of December 31, 2023 , 24 months were remaining on the sublease. The Company expects to recognize $ 4.8 million of sublease income over the lease term that commenced in October 2022. At December 31, 2023, $ 2.9 million sublease income is expected to be recognized over the remaining lease term. In addition, on February 28, 2023, the Company signed a second agreement to sublease an additional 25 % of its corporate headquarters (21 st floor) for a period of 77 months, which commenced on December 1, 2023. The Company expects to recognize additional sublease income of $ 9.1 million over the lease term. At December 31, 2023, $ 9.0 million sublease income is expected to be recognized over the remaining lease term. Rent expense, net of sublease income, is reported within restructuring and related charges for the year ended December 31, 2023, in the consolidated statements of operations. The Company is currently in the process of fully vacating and potentially subleasing an additional floor (20 th floor). Information about the Company's operating leases is as follows: December 31, 2023 December 31, 2022 Weighted average remaining lease term (in years) 5.9 years 6.8 years Weighted average discount rate per annum 11.8 % 11.8 % Year Ended December 31, 2023 2022 Operating lease cost (including variable costs) $ 11,159 $ 10,917 Variable costs (including non-lease components) $ 3,164 $ 2,930 Sublease income $ 2,679 $ 189 Cash paid for amounts included in the measurement of $ 7,931 $ 7,540 Future minimum lease payments and sublease income as of December 31, 2023 under commenced non-cancelable operating leases are as follows (in thousands): Fiscal Year Minimum Lease Sublease Income Net Minimum Lease Payments for Operating Leases 2024 $ 8,086 $ ( 2,877 ) $ 5,209 2025 8,135 ( 2,952 ) 5,183 2026 7,821 ( 1,381 ) 6,440 2027 7,395 ( 1,430 ) 5,965 2028 7,355 ( 1,480 ) 5,875 Thereafter 10,225 ( 2,058 ) 8,167 Total future minimum payments (receipts) 49,017 $ ( 12,178 ) $ 36,839 Imputed interest ( 14,320 ) Total operating lease liabilities 34,697 Less: current portion of operating lease liabilities 4,323 Operating lease liabilities, net of current portion $ 30,374 Other Commitments In the normal course of business, the Company enters into various contractual and legally binding purchase commitments. As of December 31, 2023 , the Company's open commitments totaled $ 9.7 million. Capital expenditure commitments as of December 31, 2023 were immaterial. The Company has entered into several license and patent agreements. Under these agreements, the Company pays annual license maintenance fees, non-refundable license issuance fees, and royalties as a percentage of net sales for the sale or sublicense of products using the licensed technology. Future payments related to these license agreements have not been included in the open commitments above, as the period of time over which the future license payments will be required to be made, and the amount of such payments, are indeterminable. The Company does not expect the license payments to be material in any particular year. Indemnification From time to time, the Company has entered into indemnification provisions under certain of its agreements in the ordinary course of business, typically with business partners, customers and suppliers. Pursuant to these agreements, the Company may indemnify, hold harmless and agree to reimburse the indemnified parties on a case-by-case basis for losses suffered or incurred by the indemnified parties in connection with any patent or other intellectual property infringement claim by any third party with respect to the Company’s products. The term of these indemnification provisions is generally perpetual from the time of the execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is typically not limited to a specific amount. In addition, the Company has entered into indemnification agreements with its officers, directors and certain other employees. With certain exceptions, these agreements provide for indemnification for related expenses including, among others, attorneys’ fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding. Litigation On November 28, 2023, a purported stockholder filed a complaint against the Company and the members of the Company’s Board in the United States District Court for the Northern District of California. The complaint has since been voluntarily dismissed. On December 12, 2023 two separate shareholder complaints were filed in the District of Delaware, The complaints asserted claims under Section 14(a) of the Exchange Act and Rule 14a-9 promulgated thereunder and Section 20(a) of the Exchange Act for allegedly causing the filing with the SEC on November 14, 2023 of a materially deficient registration statement on Form S-4. Among other remedies, the plaintiffs sought to enjoin a stockholder vote on the proposed Merger. The Company is reviewing the complaints and has not yet formally responded to them. On December 13, 2023, a complaint was filed in the Delaware Court of Chancery against SomaLogic and certain officers and directors alleging Breach of Fiduciary Duty and Aiding and Abetting Breach of Fiduciary Duty. This complaint also sought an injunction postponing the proposed transaction, which was denied by the Court on January 4, 2024. The non-injunctive claims, including breach of fiduciary duty, are still being litigated. Litigation is inherently uncertain and there can be no assurance regarding the outcome. Whether or not any plaintiffs’ claim is successful, this type of litigation may result in significant costs and divert management’s attention and resources, which could adversely affect the operation of the Company. Between October 24, 2023 and January 3, 2024, SomaLogic received 16 letters from purported shareholders demanding that SomaLogic allow the inspection of its books and records and/or make corrective disclosures to its registration statement. Additional lawsuits against the Company and certain of our officers or directors may be filed in the future. If additional similar complaints are filed, absent new or different allegations that are material, the Company will not necessarily announce such additional filings. In the normal course of business, the Company is from time to time involved in legal proceedings or potential legal proceedings, including matters involving employment, intellectual property, or others. Although the results of litigation and claims cannot be predicted with certainty, the Company currently believes that the final outcome of any currently pending matters would not have a material adverse effect on our business, operating results, financial condition, or cash flows. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors. |
Fair Value of Financial Instrum
Fair Value of Financial Instruments | 12 Months Ended |
Dec. 31, 2023 | |
Fair Value Disclosures [Abstract] | |
Fair Value of Financial Instruments | 8. Fair Value of Financial Instruments The following tables summarize the Company's financial instruments by significant investment category measured at fair value on a recurring basis within the fair value hierarchy (in thousands): Fair Value Measurements At Reporting Date Using Total Quoted Prices in Active Markets For Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) As of December 31, 2023 Cash and cash equivalents: Money market funds $ 35,385 $ 35,385 $ — $ — Total cash and cash equivalents $ 35,385 $ 35,385 $ — $ — Short-term investments: U.S. treasury securities $ 63,191 $ — $ 63,191 $ — Total short-term investments $ 63,191 $ — $ 63,191 $ — Total assets measured at fair value $ 98,576 $ 35,385 $ 63,191 $ — Fair Value Measurements At Reporting Date Using Total Quoted Prices in Active Markets For Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) As of December 31, 2022 Cash and cash equivalents: Money market funds $ 53,894 $ 53,894 $ — $ — Total cash and cash equivalents $ 53,894 $ 53,894 $ — $ — Short-term investments: U.S. treasury securities $ 84,475 $ 84,475 $ — $ — Total short-term investments $ 84,475 $ 84,475 $ — $ — Total assets measured at fair value $ 138,369 $ 138,369 $ — $ — There were no transfers within the hierarchy and no changes in the valuation techniques used during the year ended December 31, 2023. The following table summarizes available-for-sale-securities (in thousands): As of December 31, 2023 Maturity (in years) Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Cash and cash equivalents: Money market funds $ 35,385 $ — $ — $ 35,385 Total cash and cash equivalents $ 35,385 $ — $ — $ 35,385 Short-term investments: U.S. treasury securities 1 or less $ 63,169 $ 22 $ — $ 63,191 Total short-term investments $ 63,169 $ 22 $ — $ 63,191 Total available-for-sale securities $ 98,554 $ 22 $ — $ 98,576 As of December 31, 2022 Maturity (in years) Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Cash and cash equivalents: Money market funds $ 53,894 $ — $ — $ 53,894 Total cash and cash equivalents $ 53,894 $ — $ — $ 53,894 Short-term investments: U.S. treasury securities 1 or less $ 84,977 $ — $ ( 502 ) $ 84,475 Total short-term investments $ 84,977 $ — $ ( 502 ) $ 84,475 Total available-for-sale securities $ 138,871 $ — $ ( 502 ) $ 138,369 As of December 31, 2023 , no ne of the available-for-sale securities held have been in an unrealized loss position for greater than 12 months. The Company does no t intend to sell these investments and it is not likely that the Company will be required to sell these investments before recovery of their amortized cost basis. No allowance for credit losses was recorded. Debt The 2014 Notes and 2019 Notes (collectively, the Convertible Notes) are not regularly traded. The estimated fair values for these securities represent Level III valuations since a fair value for these securities cannot be determined by using readily observable inputs or measures, such as market prices. Fair values were estimated using pricing models and risk-adjusted value ranges. The estimated fair value of the 2019 Notes was $ 58.2 million and $ 48.4 million as of December 31, 2023 and 2022, respectively. The carrying value of the 2014 Notes approximates fair value as the interest rate and terms are reflective of the rate the Company could obtain on debt with similar terms and conditions. The estimated fair value of the Term Loan Facility also represents a Level III valuation since the value cannot be determined by using readily observable inputs or measures, such as market prices. The fair value of the Company's Term Loan Facility was estimated using a discounted cash flow model and current market interest rate data for similar loans. The carrying value of the Company's lines of Term Loan Facility approximates fair value as interest rates applied to the underlying debt are adjusted quarterly to market interest rates. |
Mezzanine Equity
Mezzanine Equity | 12 Months Ended |
Dec. 31, 2023 | |
Equity [Abstract] | |
Mezzanine Equity | . Mezzanine Equity Series B Redeemable Preferred Stock On January 23, 2022, the Company entered into separate Series B Convertible Preferred Stock Purchase Agreements (collectively, the Purchase Agreements) with Casdin Private Growth Equity Fund II, L.P. and Casdin Partners Master Fund, L.P. (together, Casdin), and Viking Global Opportunities Illiquid Investments Sub Master LP and Viking Global Opportunities Drawdown LP (together, Viking, and together with Casdin, the Lenders), whereby the Company issued and sold an aggregate of $ 225.0 million of convertible preferred stock, consisting of: (i) 112,500 shares of the Company’s Series B-1 Convertible Preferred Stock, par value $ 0.001 per share (the Series B-1 Preferred Stock), at a purchase price of $ 1,000 per share; and (ii) 112,500 shares of the Company’s Series B-2 Convertible Preferred Stock, par value $ 0.001 per share (the Series B-2 Preferred Stock, and together with the Series B-1 Preferred Stock, the Series B Preferred Stock or the Series B Redeemable Preferred Stock) at a purchase price of $ 1,000 per share (together with the issuance of shares of Series B Preferred Stock in connection with the conversion of the Bridge Loans, the Private Placement). On the Private Placement Closing Date, 225,000 shares of Series B Preferred Stock were issued in accordance with the Purchase Agreements and the Bridge Loans converted into 30,559 shares of Series B Preferred Stock, for a total of 255,559 shares of Series B Preferred Stock. The Company recorded the Series B Preferred Stock as mezzanine equity at its fair value upon issuance, net of any issuance costs, on the consolidated balance sheets as it has features, such as change of control and liquidation preference, which are outside of the Company’s control. The Purchase Agreements were accounted for as forward sales contracts at fair value in accordance with the authoritative accounting guidance as the Series B Preferred Stock included certain contingent redemption features that created an obligation for the Company to repurchase its shares. The fair value of the payable portion of the forward sales contracts was determined using a Monte Carlo Simulation, which relies on significant assumptions regarding the estimated yield and term of the Series B Preferred Stock. The components of the carrying value of the Series B Preferred Stock as of December 31, 2023 and 2022 were as follows (in thousands): Proceeds from Purchase Agreements $ 225,000 Proceeds from Bridge Loans 25,000 Change in fair value of Forward Purchase Agreements 60,081 Change in the fair value of Bridge Loans 13,719 Less equity issuance costs ( 12,547 ) Total Series B Redeemable Preferred Stock $ 311,253 The Series B Preferred Stock ranks senior to the Company's common stock with respect to dividend rights, redemption rights and rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company. The holders of Series B Preferred Stock are entitled to participate in all dividends declared on the Company's common stock on an as-converted basis. |
Shareholders' Deficit
Shareholders' Deficit | 12 Months Ended |
Dec. 31, 2023 | |
Equity [Abstract] | |
Shareholders' Deficit | 10. Shareholders' Deficit Stock Repurchase Program On November 23, 2022, the Company’s board of directors authorized the repurchase of up to $ 20.0 million in shares of the Company’s common stock in the open market or in negotiated transactions through December 31, 2023. The Company repurchased a total of 2,709,703 shares of common stock under the program at a cost of $ 5.4 million, excluding commission fees, for an average of $ 1.98 per share for the year ended December 31, 2023. Repurchases under the program were able to be suspended or discontinued at any time at the Company’s discretion, and on October 4, 2023, the Company terminated the program in connection with the announcement of the merger agreement with SomaLogic. Common Shares Reserved As of December 31, 2023, the Company had reserved shares of common stock for future issuance under equity compensation plans as follows (in thousands): Securities To Be Issued Upon Exercise Of Options Securities To Be Issued Upon Release Of Restricted Stock Number Of Remaining Securities Available For Future Issuance 2022 Inducement Equity Incentive Plan 7,595 1,277 208 2011 Equity Incentive Plan 1,640 5,964 4,656 2017 Inducement Award Plan 59 2 — 2017 Employee Stock Purchase Plan — — 1,581 Total common stock reserved for future issuance 9,294 7,243 6,445 |
Stock-based Compensation
Stock-based Compensation | 12 Months Ended |
Dec. 31, 2023 | |
Share-Based Payment Arrangement [Abstract] | |
Stock-based Compensation | 11. Stock-based Compensation Equity Compensation Plans 2011 Equity Incentive Plan In January 2011, the Company's board of directors adopted the 2011 Equity Incentive Plan (2011 Plan) under which incentive stock options, non-statutory stock options, RSUs, stock appreciation rights, PSUs, and performance shares may be granted to its employees, directors, and consultants. 2022 Inducement Equity Incentive Plan In April 2022, the Company's board of directors adopted the 2022 Inducement Plan and reserved 9.5 million shares of common stock for the issuance of equity-based awards, including non-statutory stock options, RSUs, restricted stock, stock appreciation rights, performance shares and PSUs. In accordance with Nasdaq listing rules, equity awards issued under the 2022 Inducement Plan are restricted to individuals who are not already employees or directors of the Company. The terms and conditions of the 2022 Inducement Plan are substantially similar to those of the 2011 Plan. The Company's board of directors sets the terms, conditions, and restrictions related to the grant of stock options, RSUs and performance-based awards under its stock-based plans, as well as employee participation in the 2017 Employee Stock Purchase Plan (ESPP). The Company's board of directors determines the number of awards to grant and also sets vesting criteria. In general, RSUs vest on a quarterly basis over a period of four years from the date of grant at a rate of 25 % on the first anniversary of the grant date and ratably each quarter over the remaining 12 quarters, or ratably over 16 quarters, subject to the employees’ continued employment. The Company may grant RSUs with different vesting terms from time to time. Stock options granted under the Company's 2022 Inducement Plan and 2011 Plan have a term of no more than ten years from the date of grant and an exercise price of at least 100 % of the fair market value of the underlying common stock on the date of grant. Generally, options vest at a rate of either 25 % on the first anniversary of the option grant date and ratably each month over the remaining period of 36 months, or ratably each month over 48 months. The Company may grant options with different vesting terms from time to time. For performance-based share awards, the Company's board of directors sets the performance objectives and other vesting provisions in determining the number of shares or value of performance units and performance shares that will be paid out. Such payout will be a function of the extent to which performance objectives or other vesting provisions have been achieved. Restricted Stock Units Number of Units Weighted-Average Balance at December 31, 2022 7,120 $ 2.58 RSU granted 3,728 $ 2.32 RSU released ( 2,970 ) $ 2.68 RSU forfeited ( 945 ) $ 2.17 Balance at December 31, 2023 6,933 $ 2.46 As of December 31, 2023 , the unrecognized compensation costs related to outstanding unvested RSUs under the Company’s equity incentive plans were $ 13.9 million. The Company expects to recognize those costs over a weighted-average period of 2.5 years. Stock Options Number of Weighted-Average Weighted- Aggregate (1) (in thousands) Balance at December 31, 2022 7,882 $ 4.43 7.9 $ — Options granted 2,609 $ 2.57 Options exercised ( 44 ) $ 1.84 Options cancelled ( 1,153 ) $ 6.84 Balance at December 31, 2023 9,294 $ 3.62 8.5 $ 439 Vested at December 31, 2023 3,497 $ 3.98 8.2 $ 78 Unvested awards at December 31, 2023 5,797 $ 3.40 8.7 $ 361 Aggregate intrinsic value as of December 31, 2023 was calculated as the difference between the closing price per share of the Company’s common stock on the last trading day of December, which was $ 2.21 , and the exercise price of the options, multiplied by the number of in-the-money options. The total intrinsic value of options exercised during the years ended December 31, 2023 and 2022 was immaterial. The total intrinsic value of options vested during the years ended December 31, 2023 and 2022 was $ 0.1 million and zero , respectively. As of December 31, 2023 , the unrecognized compensation costs related to outstanding unvested options under the Company’s equity incentive plans were $ 12.4 million. The Company expects to recognize those costs over a weighted-average period of 2.3 years. The weighted average assumptions used to estimate the fair value of options granted were as follows: Year Ended December 31, 2023 2022 Stock options Weighted average expected volatility 97.1 % 91.8 % Weighted average expected term 4.7 years 4.3 years Weighted average risk-free interest rate 3.9 % 2.6 % Dividend yield — — Weighted-average fair value per share $ 1.49 $ 2.21 Expected Term —The expected term of options granted represents the period of time that the options are expected to be outstanding and is derived by analyzing historical exercise behavior. Expected Volatility —The estimated volatility was based on the historical volatility of the common stock of the Company. Risk-Free Interest Rate —The risk-free interest rate is the implied yield in effect at the time of the option grant based on U.S. Treasury securities with contract maturities similar to the expected term of the Company’s stock options. Dividend Rate —The Company has not paid any cash dividends on common stock since inception and does not anticipate paying any dividends in the foreseeable future. Consequently, an expected dividend yield of zero was used. Performance-based Awards The Company previously granted PSUs to certain executive officers and senior-level employees with the number of PSUs ultimately earned under these awards being calculated by comparing the Total Shareholder Return (TSR) of the Company’s common stock over the applicable three-year period against the TSR of a defined group of peer companies. The Company’s relative performance against its peer group determined the payout, which could range from 0 % to 200 % of the base awards. As these awards required continuous service in order to vest and these officers and senior level employees are no longer with the Company, they were canceled as of June 30, 2023. In July 2023, the Company granted performance-based restricted stock units to certain executive officers that will vest in the first quarter of 2024 based upon the achievement of specified revenue and EBITDA targets for the twelve months ended December 31, 2023, and the executive’s continued employment with the Company. Stock-based compensation expense is being recognized over the requisite service period, as it is deemed probable the Company will satisfy the performance measures. Activity under the performance-based awards was as follows: Number of Units Weighted-Average Balance at December 31, 2022 453 $ 4.81 PSU granted 309 $ 2.42 PSU released ( 52 ) $ 9.60 Performance adjustment for 2020 awards ( 401 ) $ 4.19 Balance at December 31, 2023 309 $ 2.42 Stock-based Compensation Expense Stock-based compensation expense is reported in the Company's consolidated statement of operations as follows (in thousands): Year Ended December 31, 2023 2022 Cost of product revenue $ 811 $ 592 Research and development expense 1,671 2,481 Selling, general and administrative expense 10,641 11,807 Total stock-based compensation expense $ 13,123 $ 14,880 |
Income Taxes
Income Taxes | 12 Months Ended |
Dec. 31, 2023 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | 12. Income Taxes The Company' loss before income taxes consists of the following (in thousands): Year Ended December 31, 2023 2022 Domestic $ ( 40,587 ) $ ( 174,041 ) International ( 33,617 ) ( 18,887 ) Loss before income taxes $ ( 74,204 ) $ ( 192,928 ) Significant components of the Company's benefit (expense) from income taxes are as follows (in thousands): Year Ended December 31, 2023 2022 Current: Federal $ — $ — State ( 197 ) ( 87 ) Foreign ( 373 ) ( 405 ) Total current tax expense ( 570 ) ( 492 ) Deferred: Federal — — State — — Foreign 118 3,322 Total deferred benefit 118 3,322 Total benefit (expense) from income taxes $ ( 452 ) $ 2,830 Reconciliation of income taxes at the statutory rate to the benefit (expense) from income taxes recorded in the statements of operations is as follows: Year Ended December 31, 2023 2022 Tax benefit at federal statutory rate 21.0 % 21.0 % State tax expense, net of federal benefit 1.3 0.8 Foreign tax expense 8.1 0.8 NOL carryforwards expiring unutilized ( 5.5 ) ( 22.8 ) Change in valuation allowance ( 21.9 ) 17.1 Federal R&D credit 0.2 0.2 Unrecognized tax benefit — 0.9 Non-deductible interest/premium — ( 0.3 ) Non-deductible loss on Forward Sale of Preferred Stock and — ( 8.0 ) R&D tax credits expiring unutilized — ( 5.2 ) Transaction costs ( 1.5 ) — Executive stock-based compensation ( 2.6 ) ( 0.8 ) Return to provision 2.5 — Other, net ( 2.0 ) ( 2.2 ) Effective tax rate ( 0.4 )% 1.5 % Significant components of the Company's deferred tax assets and liabilities are as follows (in thousands): Year Ended December 31, 2023 2022 Deferred tax assets: Net operating loss carryforward $ 96,242 $ 85,182 Reserves and accruals 3,152 3,943 Depreciation and amortization 564 563 Capitalized R&D costs 5,962 3,840 Tax credit carryforwards 15,463 14,456 Stock-based compensation 1,143 2,064 Right-of-use lease liabilities 7,782 8,663 Total gross deferred tax assets 130,308 118,711 Valuation allowance on deferred tax assets ( 124,124 ) ( 107,893 ) Total deferred tax assets, net of valuation allowance 6,184 10,818 Deferred tax liabilities: Fixed assets and intangibles ( 54 ) ( 3,913 ) Right-of-use assets ( 6,836 ) ( 7,729 ) Total deferred tax liabilities ( 6,890 ) ( 11,642 ) Net deferred tax liability $ ( 706 ) $ ( 824 ) Deferred tax liability per balance sheet $ ( 841 ) $ ( 1,055 ) Less deferred tax assets included in other long-term assets 135 231 Net deferred tax liability $ ( 706 ) $ ( 824 ) Utilization of the net operating loss carryforwards and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by Section 382 of the Internal Revenue Code of 1986, as amended, and similar state provisions. The Company completed its Section 382 Study through December 31, 2022 and determined that an ownership change occurred on April 4, 2022 due to the issuance of preferred equity. As a result of this ownership change, a portion of net operating loss (NOL) carryforwards and all R&D credits will expire unutilized. Further limitations are also expected as a result of the merger with SomaLogic that occurred on January 5, 2024. The Company establishes a valuation allowance for deferred tax assets if the Company determines it is more likely than not the related tax benefit will not be realized. The Company relies on several factors when assessing the realizability of deferred tax assets, including historical financial results, the Company's ability to recover net operating loss carry-forwards, the projected future operating results, and the Company's ability to use tax planning strategies. The valuation allowances of $ 124.1 million and $ 107.9 million as of December 31, 2023 and 2022, respectively, primarily relate to temporary tax differences, net operating losses and research and development credits generated in the current and prior years. The Company believes it is more likely than not that U.S. federal and state, Canada and Netherlands deferred tax assets relating to temporary differences, net operating losses and research and development credits are not realizable. As such, full valuation allowances have been applied against the deferred tax assets relating to jurisdictions of the U.S. federal and state, Canada and Netherlands. A reconciliation of the beginning and ending amounts of the valuation allowance for the years ended December 31, 2023 and 2022 is as follows (in thousands): Valuation Allowance December 31, 2021 $ 141,087 Charges to earnings — Charges to other accounts ( 33,194 ) December 31, 2022 107,893 Charges to earnings — Charges to other accounts 16,231 December 31, 2023 $ 124,124 As of December 31, 2023 , the Company had net operating loss carryforwards for U.S. federal income tax purposes of $ 363.5 million, and U.S. federal research and development tax credits of $ 0.5 million, which begin expiring in 2042. As of December 31, 2023 , the Company had net operating loss carryforwards for state income tax purposes of $ 220.4 million, which will expire through 2043, and California research and development tax credits of $ 14.0 million, which do not expire. As of December 31, 2023 , we had foreign net loss carryforwards of $ 36.6 million, which will begin to expire in 2041, and foreign tax credit carryforwards of $ 6.9 million, which begin to expire in 2037. The aggregate changes in the balance of the Company's gross unrecognized tax benefits during 2023, and 2022 were as follows (in thousands): December 31, 2021 $ 8,515 Increases in balances related to tax positions during a prior 154 Increases in balances related to tax positions taken during — Decreases in balances related to tax positions taken during prior ( 1,697 ) December 31, 2022 6,972 Increases in balances related to tax positions during a prior 105 Decreases in balances related to tax positions taken during ( 138 ) December 31, 2023 $ 6,939 As of December 31, 2023 , there were no unrecognized tax benefits that, if recognized, would reduce the Company's effective tax rate. The Company does not anticipate that existing unrecognized tax benefits will significantly increase or decrease within the next 12 months. Accrued interest and penalties related to unrecognized tax benefits was included in the income tax provision. The amount was immaterial as of December 31, 2023 and 2022. The Company files income tax returns in the United States, its various states, and in certain foreign jurisdictions. As a consequence of having operating loss carryforwards, all tax years are open to federal and state examination in the United States. Tax years from 2012 are open to examination in various foreign countries. |
Segment Reporting
Segment Reporting | 12 Months Ended |
Dec. 31, 2023 | |
Segment Reporting [Abstract] | |
Segment Reporting | 13. Segment Reporting The Company operates in two reportable segments: proteomics and genomics. Each segment is identified by its unique portfolio of products. Proteomics includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. Genomics includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. During 2023, the CODM began using gross profit to measure the operating performance of the segments. The Company determines each segment’s gross profit by subtracting cost of product and service revenues from segment revenues. The Company does not prepare or report segmented balance sheet information as the CODM does not use the information to assess segment operating performance. The segments adhere to the same accounting policies as the Company as a whole. The Company's business segment information was as follows (in thousands): Year Ended December 31, 2023 2022 Revenue: Proteomics $ 63,883 $ 52,502 Genomics 42,457 45,446 Total revenue $ 106,340 $ 97,948 Gross profit: Proteomics $ 26,239 $ 20,041 Genomics 24,211 17,010 Total gross profit $ 50,450 $ 37,051 Depreciation & amortization: Proteomics $ 12,072 $ 12,223 Genomics 601 230 Total depreciation & amortization $ 12,673 $ 12,453 |
401(K) Plan
401(K) Plan | 12 Months Ended |
Dec. 31, 2023 | |
Retirement Benefits [Abstract] | |
401(K) Plan | 15. 401(k) Plan The Company sponsors a 401(k) savings plan for its employees in the United States that stipulates that eligible employees may elect to contribute to the plan, subject to certain limitations, up to the lesser of 90 % of eligible compensation or the maximum amount allowed by the U.S. Internal Revenue Service. In 2019 and onward, the employee match formula was 100 % up to $ 3,000 annually. Employer matching contributions to the 401(k) plan were $ 0.5 million and $ 0.6 million for the years ended December 31, 2023 and 2022 . |
Restructuring and Related Charg
Restructuring and Related Charges | 12 Months Ended |
Dec. 31, 2023 | |
Restructuring and Related Activities [Abstract] | |
Restructuring and Related Charges | 14. Restructuring and Related Charges Beginning with the appointment of the Company’s new management team in April 2022 and as further announced in August 2022, the Company has implemented a restructuring plan, including a reduction in force, to improve operational efficiency, achieve cost savings and align the Company’s workforce to the future needs of the business. In addition to the reduction in force, the Company is reducing leased office space, optimizing its manufacturing footprint and streamlining support functions. The Company is developing a more disciplined cost management culture throughout its organization by investing in training and advanced information systems. The Company records restructuring and related charges as incurred. These items are classified within restructuring and related charges in the consolidated statements of operations for the year ended December 31, 2023 , and primarily include severance costs as well as facility costs (net of sublease income) for leased space in South San Francisco that the Company has vacated as part of the restructuring plan. The Company recognized restructuring and related charges of $ 7.1 million and $ 9.7 million for the years ended December 31, 2023 and 2022, respectively. The Company expects to relieve the majority of the existing liability for restructuring charges primarily related to employee severance in 2024. Ongoing restructuring charges will continue to be incurred for facility related costs through the termination of the facility leases. These estimates are subject to a number of assumptions, and actual results may differ. The following table summarizes the change in the Company’s restructuring and other related liabilities for the years ended December 31, 2023 and 2022 (in thousands): Severance (1) Facility Other (2) Total Balance at December 31, 2021 $ — $ — $ — $ — Restructuring and related charges 5,849 2,885 998 9,732 Cash payments ( 1,835 ) ( 2,885 ) ( 979 ) ( 5,699 ) Balance at December 31, 2022 $ 4,014 $ — $ 19 $ 4,033 Restructuring and related charges 2,379 4,160 537 7,076 Cash payments ( 5,568 ) ( 4,160 ) ( 556 ) ( 10,284 ) Balance at December 31, 2023 $ 825 $ — $ — $ 825 (1) Restructuring liabilities are recorded in accrued compensation and related benefits on the consolidated balance sheets. (2) Other restructuring liabilities are comprised mainly of sublease commissions and are recorded in other accrued liabilities on the consolidated balance sheets. The Company’s restructuring and related charges by segment and corporate were as follows (in thousands): Year Ended December 31, 2023 2022 Restructuring: Proteomics $ 1,010 $ 1,363 Genomics 714 1,273 Corporate expenses 5,352 7,096 Total restructuring and related charges $ 7,076 $ 9,732 |
Subsequent Event
Subsequent Event | 12 Months Ended |
Dec. 31, 2023 | |
Subsequent Events [Abstract] | |
Subsequent Event | 16. Subsequent Event SomaLogic Merger On January 5, 2024, the Company completed the previously announced Merger pursuant to the Agreement and Plan of Merger, dated as of October 4, 2023 (the “Merger Agreement”), by and among the Company, SomaLogic, and Martis Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (Merger Sub). Pursuant to the Merger Agreement, Merger Sub merged with and into SomaLogic, with SomaLogic surviving as a wholly owned subsidiary of Standard BioTools. At the consummation of the Merger, each issued and outstanding share of common stock of SomaLogic, was converted into the right to receive 1.11 shares of common stock of Standard BioTools, and cash in lieu of fractional shares. At the effective time of the Merger, SomaLogic’s common stockholders owned approximately 57 %, and the Company’s common stockholders owned approximately 43 %, of the outstanding shares of common stock of the combined company on a fully diluted basis. In addition, as of the effective time of the Merger, the Company assumed each SomaLogic stock incentive plan, outstanding option to purchase shares of SomaLogic common stock and outstanding restricted stock units convertible into shares of SomaLogic common stock, whether vested or unvested. In addition, as of the Effective Time, each SomaLogic warrant was treated in accordance with its terms. Due to the limited time between the Merger date and the filing of this Annual Report, it is not practicable for the Company to disclose the preliminary allocation of the purchase price to assets acquired and liabilities assumed. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2023 | |
Accounting Policies [Abstract] | |
Basis of Presentation and Consolidation | Basis of Presentation and Consolidation The accompanying consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (U.S. GAAP) and include the accounts of the Company's wholly owned subsidiaries. As of December 31, 2023 , the Company had wholly owned subsidiaries in Singapore, Canada, the Netherlands, Japan, France, Italy, the United Kingdom, China, Germany and Norway. All subsidiaries, except for Singapore, use their local currency as their functional currency. The Singapore subsidiary uses the U.S. dollar as its functional currency. All intercompany transactions and balances have been eliminated in consolidation. |
Use of Estimates | Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates on historical experience, the current economic environment and on various other assumptions believed to be reasonable, which together form the basis for making judgments about the carrying values of assets and liabilities. These accounting matters included but were not limited to inventory and related reserves, the carrying value of goodwill and other long-lived assets, and the potential outcome of uncertain tax positions that have been recognized in the Company's financial statements or tax returns. The Company also uses significant judgment in determining the fair value of financial instruments, including debt and equity instruments. Actual results could differ materially from these estimates and could have a material adverse effect on the Company's consolidated financial statements. |
Foreign Currency | Foreign Currency Assets and liabilities of non-U.S. subsidiaries that use their local currency as their functional currency are translated into U.S. dollars at exchange rates in effect on the balance sheet date. Income and expense accounts are translated at monthly average exchange rates during the year. The adjustments resulting from the foreign currency translations are recorded in accumulated other comprehensive loss, a separate component of stockholders’ equity (deficit). |
Revenue Recognition | Revenue Recognition The Company generates revenue primarily from the sale of its products and services. Product revenue is derived from the sale of instruments and consumables, including IFCs, assays and reagents. Service revenue is derived from the sale of instrument service contracts, repairs, installation, training and other specialized product support services. The Company also generates revenue from product development agreements, license and royalty agreements, and grants. Revenue is reported net of any sales, use and value-added taxes the Company collects from customers as required by government authorities. Research and development cost includes costs associated with development and grant revenue. The Company recognizes revenue based on the amount of consideration it expects to receive in exchange for the goods and services it transfers to the customer. The Company's commercial arrangements typically include multiple distinct products and services, and the Company allocates revenue to these performance obligations based on their relative standalone selling prices. Standalone selling prices (SSP) are generally determined using observable data from recent transactions. In cases where sufficient data is not available, the Company estimates a product’s SSP using a cost plus a margin approach or by applying a discount to the product’s list price. Product Revenue The Company recognizes product revenue at the point in time when control of the goods passes to the customer, and the Company has an enforceable right to payment. This generally occurs either when the product is shipped from one of the Company's facilities or when it arrives at the customer’s facility, based on the contractual terms. Customers do not have a unilateral right to return products after delivery. Invoices are generally issued at shipment or in advance of service and become due in 30 to 60 days. The Company sometimes perform shipping and handling activities after control of the product passes to the customer. The Company has made an accounting policy election to account for these activities as product fulfillment activities rather than as separate performance obligations. Service and Other Revenue The Company recognizes revenue from repairs, maintenance, installation, training and other specialized product support services at the point in time the work is completed. Installation and training services are generally billed in advance of service. Repairs and other services are generally billed at the point the work is completed. Revenue associated with instrument service contracts is recognized on a straight-line basis over the life of the agreement, which is generally one to three years . The Company believes this time-elapsed approach is appropriate for service contracts because the Company provides services on demand throughout the term of the agreement. Invoices are generally issued in advance of service on a monthly, quarterly, annual or multi-year basis. Payments made in advance of service are reported on the Company's consolidated balance sheet as deferred revenue. Other revenue consists of license and royalty revenue and grant revenue. The Company recognizes revenue from license agreements when the license is transferred to the customer and the customer is able to use and benefit from the license. For contracts that include sales-based royalties, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied. The Company receives grants from various entities to perform research and development activities over contractually defined periods. Grant revenue is not accounted for under ASC Topic 606, Revenue from Contracts with Customers , as the grant agreement is not with a customer. As there is no authoritative U.S. GAAP guidance for grants awarded to for-profit entities, the Company has applied the guidance in ASC Topic 958, Not-for-Profit Entities by analogy. Revenue is generally recognized provided that the conditions under which the grants were provided have been met and any remaining performance obligations are perfunctory. Significant Judgments Applying the revenue recognition practices discussed above often requires significant judgment. Significant judgment is required when interpreting commercial terms in sales agreements and determining when control of goods and services passes to the customer. Judgment is also required when identifying performance obligations, estimating SSP and allocating purchase consideration in agreements that include multiple performance obligations. Any material changes created by errors in judgment could have a material effect on the Company's operating results and overall financial condition. |
Cash and Cash Equivalents | Cash and Cash Equivalents The Company considers all highly liquid financial instruments with maturities at the time of purchase of three months or less to be cash equivalents. Cash and cash equivalents balance at December 31, 2023, and 2022 represent cash on deposit with banks and money market funds. |
Short-term Investments | Short-term Investments Short-term investments are comprised of U.S treasury securities that mature within one year. The Company classifies its short-term investments as available-for-sale and records such assets at estimated fair value in the consolidated balance sheets. Any unrealized gains and losses from short-term investments are reported as a component of other comprehensive income (loss) within the consolidated statements of comprehensive loss and as a separate component of stockholders’ equity (deficit). The Company evaluates its short-term investments to assess whether investments with unrealized loss positions are other-than-temporarily impaired. An investment is considered to be other-than-temporarily impaired if the impairment is related to deterioration in credit risk or if it is likely that the Company will sell the securities before the recovery of their cost basis. No investment has been assessed as other than temporarily impaired. Realized gains and losses are calculated on the specific identification method and are recorded as interest income (loss). There were no realized gains and losses from sales of short-term investments during any of the periods presented. The Company excludes accrued interest from the fair value and amortized cost basis of its short-term investments. |
Accounts Receivable, net | Accounts Receivable, net Trade accounts receivable are recorded at net invoice value. The Company reviews its exposure to accounts receivable and provides allowances of specific amounts if collectability is no longer reasonably assured based on historical experience and specific customer collection issues. The Company evaluates such allowances on a regular basis and adjust them as needed. |
Concentrations of Business and Credit Risk | Concentrations of Business and Credit Risk Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents, short-term investments, and accounts receivable. The Company's cash, cash equivalents, and short-term investments may consist of deposits held with banks, money market funds, and other highly liquid investments that may at times exceed federally insured limits. Cash equivalents and short-term investments are financial instruments that potentially subject the Company to concentrations of risk. Under the Company's investment policy, the Company invests exclusively in securities issued by the U.S. government or U.S. government agencies, or in government money-market funds. The goals of the Company's investment policy, in order of priority, are to: preserve capital, meet liquidity needs, and optimize returns. For these reasons, management believes that the Company is not exposed to significant credit risk. The Company generally does not require collateral to support credit sales. To reduce credit risk, the Company performs credit evaluations of its customers. The Company's products include components that are currently procured from a single source or a limited number of sources. The Company believes that other vendors would be able to provide similar components; however, the qualification of such vendors may require start-up time. In order to mitigate any adverse impacts from a disruption of supply, the Company attempts to maintain an adequate supply of critical limited-source components. |
Inventories, net | Inventories, net Inventories are stated at the lower of cost (on a first-in, first-out basis) or net realizable value. Inventory costs include direct materials, direct labor, and normal manufacturing overhead. The Company regularly reviews inventory for excess and obsolete products and components. Significant judgment is required in determining provisions for slow-moving, excess, and obsolete inventories which are recorded when required to reduce inventory values to their estimated net realizable values based on product life cycle, development plans, product expiration, discontinuance of product lines, and quality issues. |
Property and Equipment, net | Property and Equipment, net Property and equipment, including leasehold improvements, are stated at cost less accumulated depreciation. Accumulated depreciation is calculated using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the estimated useful lives of the assets or the remaining term of the lease, whichever is shorter. The estimated useful lives of the Company's property and equipment are generally as follows: computer equipment and software, three to four years ; laboratory and manufacturing equipment, two to seven years ; and office furniture and fixtures, five years . |
Leases | Leases At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. Lease terms are determined at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. For its long-term operating leases, the Company recognizes a lease liability and a right-of-use asset (ROU) on its consolidated balance sheets. ROU assets represent the Company's right-to-use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. The lease liability is determined at the lease commencement date based on the present value of lease payments over the lease term. As most of the Company's leases do not provide an implicit rate, the Company generally uses its incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a term similar to the lease arrangement. Significant judgment is required in determining the incremental collateralized borrowing rate. The ROU asset is based on the lease liability, adjusted for any prepaid or deferred rent. Lease expense is recognized on a straight-line basis over the lease term. Sublease income from an operating lease is recognized on a straight-line basis over the sublease term. The Company does not have any finance leases. The Company elected the short-term lease recognition exemption for all leases that qualify. For those leases that qualify, the Company will not recognize ROU assets or lease liabilities for leases with an initial lease term of one year or less. The Company also elected not to separate lease and nonlease components for the Company's building leases. The nonlease components are generally variable in nature and are expected to represent most of the Company's variable lease costs. Variable costs are expensed as incurred. The Company has taken a portfolio approach for its vehicle leases by country. |
Business Combinations | The Company has completed acquisitions of businesses in the past and may acquire additional businesses or technologies in the future. The results of businesses acquired in a business combination are included in the Company's consolidated financial statements from the date of acquisition. The Company allocates the purchase price, which is the sum of the consideration provided in a business combination, to the identifiable assets and liabilities of the acquired business at their acquisition date fair values. Determining the fair value of assets acquired and liabilities assumed requires management to use significant judgment and estimates, including the selection of valuation methodologies and estimates of future revenue. |
Goodwill | Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. The Company's intangible assets include developed technology, patents and licenses. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets’ respective estimated useful lives. Judgment is needed to assess the factors that could indicate an impairment of intangible assets. Goodwill and intangible assets with indefinite lives are not subject to amortization but are tested for impairment on an annual basis during the fourth quarter or whenever events or changes in circumstances indicate the carrying amount of these assets may not be recoverable. Events or changes in circumstances that could affect the likelihood that the Company will be required to recognize an impairment charge include, but are not limited to, declines in the Company's stock price or market capitalization, economic downturns and other macroeconomic events, declines in the Company's market share or revenues, or significant litigation. Any impairment charges could have a material adverse effect on the Company's operating results and net asset value in the period in which the Company recognizes the impairment charge. In evaluating goodwill and intangible assets with indefinite lives for indications of impairment, the Company first conducts an assessment of qualitative factors to determine whether it is more likely than not that the fair value of each of the Company's reporting units is less than its carrying amount. If the Company determines that it is more likely than not that the fair value of each of its reporting units is less than its carrying amount, the Company compares the fair value of each of its reporting units to its carrying value. If the fair value of each of the Company's reporting units exceeds its carrying value, goodwill is not considered impaired, and no further analysis is required. If the carrying value of each of the Company's reporting units exceeds its fair value, then an impairment loss equal to the difference would be recorded to goodwill. |
Intangible Assets and Other Long-Lived Assets | The Company evaluates its long-lived assets, including finite-lived intangibles, for indicators of possible impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If any indicator of impairment exists, the Company assesses the recoverability of the affected long-lived assets by determining whether the carrying value of the asset can be recovered through undiscounted future operating cash flows. If impairment is indicated, the Company estimates the asset’s fair value using future discounted cash flows associated with the use of the asset and adjust the carrying value of the asset accordingly. |
Series B Redeemable Preferred Stock | Series B Redeemable Preferred Stock The Purchase Agreements (as described in Note 9) for the issuance of shares of Series B Redeemable Preferred Stock were accounted for as forward sales contracts at fair value in accordance with ASC Topic 480, Distinguishing Liabilities from Equities . The Series B Redeemable Preferred Stock was classified as mezzanine equity and recorded at fair value upon issuance, net of issuance costs, due to its redemption features that are outside of the Company’s control. Mezzanine equity is presented separately on the consolidated balance sheets between liabilities and shareholders’ equity because it shares characteristics of both. In the year ended December 31, 2022, the Company recognized a $ 60.1 million loss on the forward sales of Series B Preferred Stock and a $ 13.7 million loss on the Bridge Loans due to the increase in the price of the Company's common stock from January 23, 2022 (the date of the Purchase Agreements and the Bridge Loan agreements) to the Private Placement Closing Date. See Note 9 for additional information. |
Restructuring and Related Charges | Restructuring and Related Charges The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. Costs for involuntary separation programs are recorded when management has approved the plan for separation, the employees are identified and made aware of the benefits they are entitled to, it is unlikely that the plan will change significantly, and if applicable, any required governmental notification is made. Costs associated with benefits that are contingent on the employee continuing to provide service are recognized over the required service period. Costs associated with leased facilities (net of sublease income, if applicable) that the Company has vacated as part of a restructuring plan are also included. |
Transaction-related Expenses | Transaction-related Expenses The Company expensed certain costs incurred related to the merger agreement with SomaLogic, described further in Note 16, including legal, advisory, accounting and other transaction-related costs. The expenses in the prior period relate to the private placement whereby the Company issued and sold an aggregate of $ 225.0 million of convertible preferred stock in connection with the conversion of the bridge loans, which closed on April 4, 2022. |
Deferred Grant Income | Deferred Grant Income Proceeds from the NIH Contract have been principally recorded as capital expenditures and to offset applicable operating costs. The non-operating income recognized from the grant proceeds received in excess of the amounts spent for capital expenditures and operating expenses is reflected on the consolidated statement of operations as surplus funding from the NIH contract. The NIH Contract met the definition of grants related to assets as the primary purpose for the payments was to fund the purchase and construction of capital assets to scale up production capacity. The Company elected to record the grants received as deferred income in accordance with International Accounting Standards (IAS) 20. Deferred grant income related to production capacity expansion is being amortized for the related assets as a reduction of depreciation expense. |
Term Loan and Convertible Notes, net | Term Loan, net The term loan is recorded at its carrying value, which includes the outstanding principal amount and the cumulative accreted final payment, less unamortized debt issuance costs. Amortization of the debt issuance costs and accretion of the final payment are reflected in interest expense. The final payment is being accreted to the carrying value of the term loan through the expected maturity of July 1, 2025 using the effective interest method. Debt issuance costs were recorded as an offset to the carrying value of the loan and are amortized over the expected term also using the effective interest method. Convertible Notes, net The Company records the 2014 Notes and 2019 Notes (as described in Note 6) at their carrying values, which includes their principal amounts plus accrued and unpaid interest. Offering-related costs, including underwriting costs, on the 2014 Notes and 2019 Notes were capitalized as debt issuance costs, recorded as an offset to the carrying value of the related Notes, and are amortized over the expected term of the related Notes using the effective interest method. |
Treasury Stock | Treasury Stock The Company uses the cost method to account for the repurchases of its common stock in accordance with ASC 505-30, Equity-Treasury Stock. The direct costs associated with settled share repurchases, including trading commissions, are reported as treasury stock in the shareholders’ equity (deficit) section of the Company's consolidated balance sheets. |
Fair Value of Financial Instruments | Fair Value of Financial Instruments The Company's financial instruments consist primarily of cash and cash equivalents, restricted cash, short-term investments, accounts receivable, accounts payable, term loan and convertible notes. The Company's cash equivalents, restricted cash, accounts receivable and accounts payable generally have short maturity or payment periods. Accordingly, their carrying values approximated their fair values at December 31, 2023 and 2022. The Company's short-term investments consist of U.S. treasury securities that are classified as available-for-sale and reported at fair value on the Company's consolidated balance sheets. The convertible notes and term loan are presented at their net carrying values. As a basis for computing fair value, the Company follows a three-tier value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level I: observable inputs such as quoted prices in active markets; Level II: inputs other than quoted prices in active markets that are observable either directly or indirectly; and Level III: unobservable inputs for which there is little or no market data, which requires the Company to develop its own assumptions. This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. The Company's cash equivalents, which include money market funds are classified as Level I because they are valued using quoted market prices. The Company's short-term investments, which include U.S. treasuries, are classified as Level II because they are valued using non-binding market consensus prices that were corroborated with observable market data, quoted market prices for similar instruments, or pricing models. The Company's convertible notes are not regularly traded, and it is difficult to estimate a reliable and accurate market price for these securities. The estimated fair values of these securities represent Level III valuations since a fair value for these securities cannot be determined by using readily observable inputs or measures, such as market prices. Fair values were estimated using pricing models and risk-adjusted value ranges. The estimated fair value of the Company's term loan also represents a Level III valuation since the value cannot be determined by using readily observable inputs or measures, such as market prices. The fair value of the Company's term loan was estimated using a discounted cash flows approach and current market interest rate data for similar loans. The carrying value of the Company's lines of term loan approximates fair value as the interest rate and terms are reflective of the rate the Company could obtain on debt with similar terms and conditions. |
Research and Development | Research and Development The Company recognizes research and development expenses in the period incurred. Research and development (R&D) expenses generally consist of personnel costs, independent contractor costs, prototype and materials expenses, allocated facilities and information technology expenses, and related overhead expenses. |
Advertising Costs | Advertising Costs The Company expenses advertising costs as incurred. The Company incurred advertising costs of $ 2.0 million and $ 3.9 million during the years ended December 31, 2023 and 2022 , respectively. |
Stock-Based Compensation | Stock-Based Compensation The Company recognizes compensation costs for all stock-based awards, including stock options, Restricted Share Units (RSUs), Performance Share Units (PSUs) and stock purchased under the Company's Employee Share Purchase Plan (ESPP), based on the grant date fair value of the award. The Company recognizes stock-based compensation expense on a straight-line basis over the requisite service periods for non-performance-based awards. For RSUs, fair value is measured based on the closing fair market value of the Company's common stock on the date of grant. For PSUs with a market condition, the Company uses a Monte Carlo simulation pricing model to incorporate the market condition effects at the grant date. The Monte Carlo pricing model requires inputs which are subjective and generally requires judgment. For PSUs with performance conditions, stock-based compensation expense is recognized over the requisite service period when the achievement of each individual performance goal becomes probable. The fair value of options and stock purchases under ESPP on the grant date is estimated using the Black-Scholes option-pricing model, which requires the use of certain subjective assumptions, including expected term, volatility, risk-free interest rate and the fair value of the Company's common stock. These assumptions generally require judgment. The Company determines the expected volatility based on the Company's historical stock price volatility generally commensurate with the estimated expected term of the stock awards. The expected term of an award is based on historical forfeiture experience, exercise activity, and the terms and conditions of the stock awards. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities approximately equal to each grant’s expected term. The Company accounts for forfeitures as they occur. |
Income Taxes | Income Taxes The Company uses the asset and liability method to account for income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Valuation allowances are provided when the expected realization of deferred tax assets does not meet a “more likely than not” criterion. The Company makes estimates and judgments about its future taxable income that are based on assumptions that are consistent with its plans and estimates. Should the actual amounts differ from the Company's estimates, the amount of the valuation allowance could be materially impacted. Changes in these estimates may result in significant increases or decreases to the Company's tax provision in a period in which such estimates are changed, which in turn would affect net income or loss. The Company recognizes the financial statement effects of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. Any interest and penalties related to uncertain tax positions are reflected in the income tax provision. |
Segment Reporting | Segment Reporting The Company operates in two reportable segments: proteomics and genomics. Each segment is identified by its unique portfolio of products. Proteomics includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. Genomics includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. The Company's CEO, who is its Chief Operating Decision Maker (CODM), measures segment performance using gross profit which is determined by subtracting cost of product and service revenues from segment revenues. Depreciation and amortization expense is included in each segment’s gross profit. |
Comprehensive Loss | Comprehensive Loss Comprehensive loss is comprised of net loss and other comprehensive income (loss). Other comprehensive income (loss) consists of unrealized gains and losses on the Company's short-term investments and foreign currency translation adjustments. Total comprehensive loss for all periods presented has been disclosed in the consolidated statements of comprehensive loss. |
Net Loss per Share | Net Loss per Share The Company's basic and diluted net loss per share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding for the period. RSUs, PSUs, stock options to purchase the Company's common stock, ESPP shares pending issuance, Series B Preferred Stock and convertible notes are considered to be potentially dilutive common shares but have been excluded from the calculation of diluted net loss per share as their effect is anti-dilutive for all periods presented. The following potentially dilutive common shares were excluded from the computations of diluted net loss per share for the periods presented because including them would have been anti-dilutive (in thousands): Year Ended December 31, 2023 2022 RSUs, PSUs, stock options and ESPP shares 16,740 15,752 Series B Preferred Stock 75,164 75,164 2019 Notes (1) 18,966 18,966 2014 Notes 10 10 Total 110,880 109,892 (1) The conversion rate is subject to adjustment upon the occurrence of certain specified events, including voluntary conversion of the 2019 Notes (as defined below) prior to the Company’s exercise of the Issuer’s Conversion Option (as defined in the 2019 Notes) or in connection with a make-whole fundamental change, entitling the holders, under certain circumstances, to a make-whole premium in the form of an increase in the conversion rate determined based on the effective date and current price of the Company’s common stock, subject to a minimum and maximum price per share. The maximum number of additional shares of common stock that may be issued under the make-whole premium is 4,741,374 shares. Refer to Note 6 for additional information on the 2019 Notes. The 2,709,703 common shares that were repurchased during the year ended December 31, 2023 have also been excluded from the Company's earnings per share and diluted earnings per share calculations. |
Recent Accounting Changes and Accounting Pronouncements | Recent Accounting Changes and Accounting Pronouncements Adoption of New Accounting Guidance From time to time, new accounting standards are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position or results of operations upon adoption. Recent Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07, Segment Reporting - Improvements to Reportable Segment Disclosures , which requires disclosure of more detailed information about a reportable segment’s expenses. The new standard is effective for fiscal years beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The amendments must be applied retrospectively, and early adoption is permitted. The Company is currently assessing the effects of adoption on its consolidated financial statements. In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures , which requires disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The new standard is effective for fiscal years beginning after December 15, 2024. The amendments may be applied prospectively or retrospectively, and early adoption is permitted. The Company is currently assessing the effects of adoption on its consolidated financial statements. |
Reclassification | Reclassification Certain amounts in the consolidated financial statements have been reclassified from their original presentation to conform to current year presentation. |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Accounting Policies [Abstract] | |
Schedule of Potential Common Shares Excluded from Computations of Net Loss Per Share Attributed to Common Stockholders | The following potentially dilutive common shares were excluded from the computations of diluted net loss per share for the periods presented because including them would have been anti-dilutive (in thousands): Year Ended December 31, 2023 2022 RSUs, PSUs, stock options and ESPP shares 16,740 15,752 Series B Preferred Stock 75,164 75,164 2019 Notes (1) 18,966 18,966 2014 Notes 10 10 Total 110,880 109,892 (1) The conversion rate is subject to adjustment upon the occurrence of certain specified events, including voluntary conversion of the 2019 Notes (as defined below) prior to the Company’s exercise of the Issuer’s Conversion Option (as defined in the 2019 Notes) or in connection with a make-whole fundamental change, entitling the holders, under certain circumstances, to a make-whole premium in the form of an increase in the conversion rate determined based on the effective date and current price of the Company’s common stock, subject to a minimum and maximum price per share. The maximum number of additional shares of common stock that may be issued under the make-whole premium is 4,741,374 shares. Refer to Note 6 for additional information on the 2019 Notes. |
Revenue and Geographic Area (Ta
Revenue and Geographic Area (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Revenue from Contract with Customer [Abstract] | |
Schedule of Disaggregation of Revenue | The following tables present the Company's revenue for the years ended December 31, 2023 and 2022, respectively, based on product type and the geographic location of customers’ facilities (in thousands): Year Ended December 31, 2023 2022 Instruments $ 37,459 $ 25,664 Consumables 41,739 46,790 Total product revenue 79,198 72,454 Service revenue 25,980 23,712 Product and service revenue 105,178 96,166 Other revenue 1,162 1,782 Total revenue $ 106,340 $ 97,948 Year Ended December 31, 2023 2022 Americas $ 46,196 $ 43,982 Europe, Middle East and Africa (EMEA) 36,201 33,136 Asia-Pacific 23,943 20,830 Total revenue $ 106,340 $ 97,948 |
Schedule of Net Long-Lived Assets Consisting of Property and Equipment in Different Geographic Areas | The Company had long-lived assets consisting of property and equipment, net of accumulated depreciation, and operating lease ROU assets, net of accumulated amortization, in the following geographic areas for each year presented (in thousands): December 31, 2023 2022 United States $ 29,646 $ 31,785 Singapore 17,097 21,178 Canada 6,231 5,394 Other Asia-Pacific 889 875 EMEA 987 303 Total $ 54,850 $ 59,535 |
Schedule of Expected Timing of Revenue Recognition | The Company expects to recognize revenue from unfulfilled performance obligations associated with service contracts that were partially completed as of December 31, 2023 in the following periods (in thousands): Fiscal Year Expected Revenue (1) 2024 13,253 2025 6,634 2026 3,061 Thereafter 1,112 Total $ 24,060 (1) Expected revenue includes both billed amounts included in deferred revenue and unbilled amounts that are not reflected in the Company's consolidated financial statements and are subject to change if the Company's customers decide to cancel or modify their contracts. Purchase orders for instrument service contracts can generally be canceled without penalty before the service period begins. |
Goodwill and Intangible Asset_2
Goodwill and Intangible Assets, net (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Schedule of Goodwill | The changes in the carrying value of goodwill by segment are as follows (in thousands): Proteomics Genomics Total Balance as of December 31, 2022 $ 85,752 $ 20,499 $ 106,251 Foreign currency translation 46 20 66 Balance as of December 31, 2023 $ 85,798 $ 20,519 $ 106,317 |
Schedule of Finite-Lived Intangible Assets | Intangible assets with finite lives include developed technology, patents and licenses. In the consolidated balance sheets, developed technology is reported separately while patents and licenses are reported in other non-current assets. Intangible assets, net, were as follows (in thousands): December 31, 2023 Gross Amount Accumulated Net Weighted- Developed technology $ 117,354 $ ( 115,954 ) $ 1,400 10.0 years Patents and licenses $ 11,250 $ ( 11,243 ) $ 7 7.0 years December 31, 2022 Gross Amount Accumulated Net Weighted- Developed technology $ 117,194 $ ( 104,594 ) $ 12,600 10.0 years Patents and licenses $ 11,247 $ ( 10,669 ) $ 578 7.0 years |
Schedule of Estimated Future Intangible Asset Amortization Expense | Based on the net carrying value of intangible assets at December 31, 2023, the Company expects annual amortization expense to be as follows (in thousands): Fiscal Year Developed Patents and Total 2024 1,400 7 1,407 Total $ 1,400 $ 7 $ 1,407 |
Balance Sheet Details (Tables)
Balance Sheet Details (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Balance Sheet Related Disclosures [Abstract] | |
Schedule of Cash and Cash Equivalents | Cash, cash equivalents and restricted cash consisted of the following (in thousands): December 31, 2023 December 31, 2022 Cash and cash equivalents $ 51,704 $ 81,309 Restricted cash 795 1,015 Total cash, cash equivalents and restricted cash $ 52,499 $ 82,324 |
Schedule of Restricted Cash | Cash, cash equivalents and restricted cash consisted of the following (in thousands): December 31, 2023 December 31, 2022 Cash and cash equivalents $ 51,704 $ 81,309 Restricted cash 795 1,015 Total cash, cash equivalents and restricted cash $ 52,499 $ 82,324 |
Schedule of Inventories, Net | Inventories, net consisted of the following (in thousands): December 31, 2023 December 31, 2022 Raw materials $ 15,539 $ 16,866 Work-in-process 282 945 Finished goods 11,753 15,245 Total inventory, gross 27,574 33,056 Allowance for excess and obsolete inventory ( 7,041 ) ( 11,583 ) Total inventories, net $ 20,533 $ 21,473 |
Schedule of Property and Equipment, Net | Property and equipment, net consisted of the following (in thousands): December 31, 2023 December 31, 2022 Laboratory and manufacturing equipment $ 35,563 $ 33,329 Leasehold improvements 13,785 12,234 Computer equipment and software 6,232 5,793 Office furniture and fixtures 1,762 1,713 Property and equipment, gross 57,342 53,069 Less accumulated depreciation and amortization ( 35,489 ) ( 29,029 ) Construction-in-progress 2,334 1,612 Property and equipment, net $ 24,187 $ 25,652 |
Schedule of Accrued Compensation and Related Benefits | Accrued compensation and related benefits, which are included in current liabilities on the consolidated balance sheets consisted of the following (in thousands): December 31, 2023 December 31, 2022 Accrued incentive compensation $ 7,337 $ 1,170 Accrued vacation 2,711 2,795 Accrued payroll taxes and other 994 1,174 Accrued restructuring 825 4,014 Accrued compensation and related benefits $ 11,867 $ 9,153 |
Other Accrued Liabilities | Other Accrued Liabilities Other accrued liabilities, which are included in current liabilities on the consolidated balance sheets consisted of the following (in thousands): December 31, 2023 December 31, 2022 Accrued commissions $ 1,010 $ 800 Accrued interest 295 318 Accrued legal expenses 964 349 Accrued taxes 1,230 1,443 Uninvoiced receipts 1,516 1,078 Accrued warranties 2,593 678 Customer advances 447 577 Accrued restructuring — 19 Accrued other 1,097 913 Other accrued liabilities $ 9,152 $ 6,175 |
Debt (Tables)
Debt (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Debt Disclosure [Abstract] | |
Schedule of Carrying Value of Debt | The carrying value of debt consists of the following (in thousands): December 31, 2023 December 31, 2022 Convertible notes: 2014 Notes $ 569 $ 568 2019 Notes, non-current — 54,047 2019 Notes, current 54,530 — Total convertible notes, net 55,099 54,615 Term loan, non-current 3,414 8,194 Term loan, current 5,000 2,083 Total debt $ 63,513 $ 64,892 |
Future Minimum Payments under Term Loan Facility including End of Term Fee Payment | Future minimum payments under the Term Loan Facility including the end of term fee payment as of December 31, 2023, are as follows (in thousands): 2024 $ 5,000 2025 2,917 7,917 End of term fee and debt issuance costs 497 Total Term Loan Facility $ 8,414 |
Commitments and Contingencies (
Commitments and Contingencies (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Commitments and Contingencies Disclosure [Abstract] | |
Schedule of Operating Leases | Information about the Company's operating leases is as follows: December 31, 2023 December 31, 2022 Weighted average remaining lease term (in years) 5.9 years 6.8 years Weighted average discount rate per annum 11.8 % 11.8 % Year Ended December 31, 2023 2022 Operating lease cost (including variable costs) $ 11,159 $ 10,917 Variable costs (including non-lease components) $ 3,164 $ 2,930 Sublease income $ 2,679 $ 189 Cash paid for amounts included in the measurement of $ 7,931 $ 7,540 |
Schedule of Future Minimum Lease Payments | Future minimum lease payments and sublease income as of December 31, 2023 under commenced non-cancelable operating leases are as follows (in thousands): Fiscal Year Minimum Lease Sublease Income Net Minimum Lease Payments for Operating Leases 2024 $ 8,086 $ ( 2,877 ) $ 5,209 2025 8,135 ( 2,952 ) 5,183 2026 7,821 ( 1,381 ) 6,440 2027 7,395 ( 1,430 ) 5,965 2028 7,355 ( 1,480 ) 5,875 Thereafter 10,225 ( 2,058 ) 8,167 Total future minimum payments (receipts) 49,017 $ ( 12,178 ) $ 36,839 Imputed interest ( 14,320 ) Total operating lease liabilities 34,697 Less: current portion of operating lease liabilities 4,323 Operating lease liabilities, net of current portion $ 30,374 |
Fair Value of Financial Instr_2
Fair Value of Financial Instruments (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Fair Value Disclosures [Abstract] | |
Schedule of Company's Financial Instruments by Significant Investment Category Measured at Fair Value on a Recurring Basis Within the Fair Value Hierarchy | The following tables summarize the Company's financial instruments by significant investment category measured at fair value on a recurring basis within the fair value hierarchy (in thousands): Fair Value Measurements At Reporting Date Using Total Quoted Prices in Active Markets For Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) As of December 31, 2023 Cash and cash equivalents: Money market funds $ 35,385 $ 35,385 $ — $ — Total cash and cash equivalents $ 35,385 $ 35,385 $ — $ — Short-term investments: U.S. treasury securities $ 63,191 $ — $ 63,191 $ — Total short-term investments $ 63,191 $ — $ 63,191 $ — Total assets measured at fair value $ 98,576 $ 35,385 $ 63,191 $ — Fair Value Measurements At Reporting Date Using Total Quoted Prices in Active Markets For Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) As of December 31, 2022 Cash and cash equivalents: Money market funds $ 53,894 $ 53,894 $ — $ — Total cash and cash equivalents $ 53,894 $ 53,894 $ — $ — Short-term investments: U.S. treasury securities $ 84,475 $ 84,475 $ — $ — Total short-term investments $ 84,475 $ 84,475 $ — $ — Total assets measured at fair value $ 138,369 $ 138,369 $ — $ — |
Schedule of Available-for-Sale Securities Reconciliation | The following table summarizes available-for-sale-securities (in thousands): As of December 31, 2023 Maturity (in years) Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Cash and cash equivalents: Money market funds $ 35,385 $ — $ — $ 35,385 Total cash and cash equivalents $ 35,385 $ — $ — $ 35,385 Short-term investments: U.S. treasury securities 1 or less $ 63,169 $ 22 $ — $ 63,191 Total short-term investments $ 63,169 $ 22 $ — $ 63,191 Total available-for-sale securities $ 98,554 $ 22 $ — $ 98,576 As of December 31, 2022 Maturity (in years) Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Cash and cash equivalents: Money market funds $ 53,894 $ — $ — $ 53,894 Total cash and cash equivalents $ 53,894 $ — $ — $ 53,894 Short-term investments: U.S. treasury securities 1 or less $ 84,977 $ — $ ( 502 ) $ 84,475 Total short-term investments $ 84,977 $ — $ ( 502 ) $ 84,475 Total available-for-sale securities $ 138,871 $ — $ ( 502 ) $ 138,369 |
Mezzanine Equity (Tables)
Mezzanine Equity (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Equity [Abstract] | |
Schedule of Carrying Value of Preferred Stock | The components of the carrying value of the Series B Preferred Stock as of December 31, 2023 and 2022 were as follows (in thousands): Proceeds from Purchase Agreements $ 225,000 Proceeds from Bridge Loans 25,000 Change in fair value of Forward Purchase Agreements 60,081 Change in the fair value of Bridge Loans 13,719 Less equity issuance costs ( 12,547 ) Total Series B Redeemable Preferred Stock $ 311,253 |
Shareholders' Deficit (Tables)
Shareholders' Deficit (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Equity [Abstract] | |
Schedule of Common Stock Reserved for Future Issuance | As of December 31, 2023, the Company had reserved shares of common stock for future issuance under equity compensation plans as follows (in thousands): Securities To Be Issued Upon Exercise Of Options Securities To Be Issued Upon Release Of Restricted Stock Number Of Remaining Securities Available For Future Issuance 2022 Inducement Equity Incentive Plan 7,595 1,277 208 2011 Equity Incentive Plan 1,640 5,964 4,656 2017 Inducement Award Plan 59 2 — 2017 Employee Stock Purchase Plan — — 1,581 Total common stock reserved for future issuance 9,294 7,243 6,445 |
Stock-based Compensation (Table
Stock-based Compensation (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Share-Based Payment Arrangement [Abstract] | |
Schedule of Activity Under Restricted Stock Units | Restricted Stock Units Number of Units Weighted-Average Balance at December 31, 2022 7,120 $ 2.58 RSU granted 3,728 $ 2.32 RSU released ( 2,970 ) $ 2.68 RSU forfeited ( 945 ) $ 2.17 Balance at December 31, 2023 6,933 $ 2.46 |
Schedule of Activity Under Stock Options | Stock Options Number of Weighted-Average Weighted- Aggregate (1) (in thousands) Balance at December 31, 2022 7,882 $ 4.43 7.9 $ — Options granted 2,609 $ 2.57 Options exercised ( 44 ) $ 1.84 Options cancelled ( 1,153 ) $ 6.84 Balance at December 31, 2023 9,294 $ 3.62 8.5 $ 439 Vested at December 31, 2023 3,497 $ 3.98 8.2 $ 78 Unvested awards at December 31, 2023 5,797 $ 3.40 8.7 $ 361 Aggregate intrinsic value as of December 31, 2023 was calculated as the difference between the closing price per share of the Company’s common stock on the last trading day of December, which was $ 2.21 , and the exercise price of the options, multiplied by the number of in-the-money options. |
Schedule of Stock-Based Compensation Determined using Black-Sholes Option-Pricing Model and Weighted Average Assumptions | The weighted average assumptions used to estimate the fair value of options granted were as follows: Year Ended December 31, 2023 2022 Stock options Weighted average expected volatility 97.1 % 91.8 % Weighted average expected term 4.7 years 4.3 years Weighted average risk-free interest rate 3.9 % 2.6 % Dividend yield — — Weighted-average fair value per share $ 1.49 $ 2.21 |
Schedule of Nonvested Performance-Based Units Activity | Activity under the performance-based awards was as follows: Number of Units Weighted-Average Balance at December 31, 2022 453 $ 4.81 PSU granted 309 $ 2.42 PSU released ( 52 ) $ 9.60 Performance adjustment for 2020 awards ( 401 ) $ 4.19 Balance at December 31, 2023 309 $ 2.42 |
Schedule of Stock-Based Compensation Expense | Stock-based compensation expense is reported in the Company's consolidated statement of operations as follows (in thousands): Year Ended December 31, 2023 2022 Cost of product revenue $ 811 $ 592 Research and development expense 1,671 2,481 Selling, general and administrative expense 10,641 11,807 Total stock-based compensation expense $ 13,123 $ 14,880 |
Income Taxes (Tables)
Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Income Tax Disclosure [Abstract] | |
Schedule of Loss Before Income Taxes | loss before income taxes consists of the following (in thousands): Year Ended December 31, 2023 2022 Domestic $ ( 40,587 ) $ ( 174,041 ) International ( 33,617 ) ( 18,887 ) Loss before income taxes $ ( 74,204 ) $ ( 192,928 ) |
Schedule of Significant Components of Provision for Income Taxes | Significant components of the Company's benefit (expense) from income taxes are as follows (in thousands): Year Ended December 31, 2023 2022 Current: Federal $ — $ — State ( 197 ) ( 87 ) Foreign ( 373 ) ( 405 ) Total current tax expense ( 570 ) ( 492 ) Deferred: Federal — — State — — Foreign 118 3,322 Total deferred benefit 118 3,322 Total benefit (expense) from income taxes $ ( 452 ) $ 2,830 |
Schedule of Reconciliation of Income Taxes at Statutory Rate to (Provision for)/Benefit (expense) from Income Taxes Recorded in Statements of Operations | Reconciliation of income taxes at the statutory rate to the benefit (expense) from income taxes recorded in the statements of operations is as follows: Year Ended December 31, 2023 2022 Tax benefit at federal statutory rate 21.0 % 21.0 % State tax expense, net of federal benefit 1.3 0.8 Foreign tax expense 8.1 0.8 NOL carryforwards expiring unutilized ( 5.5 ) ( 22.8 ) Change in valuation allowance ( 21.9 ) 17.1 Federal R&D credit 0.2 0.2 Unrecognized tax benefit — 0.9 Non-deductible interest/premium — ( 0.3 ) Non-deductible loss on Forward Sale of Preferred Stock and — ( 8.0 ) R&D tax credits expiring unutilized — ( 5.2 ) Transaction costs ( 1.5 ) — Executive stock-based compensation ( 2.6 ) ( 0.8 ) Return to provision 2.5 — Other, net ( 2.0 ) ( 2.2 ) Effective tax rate ( 0.4 )% 1.5 % |
Schedule of Significant Components of Deferred Tax Assets and Liabilities | Significant components of the Company's deferred tax assets and liabilities are as follows (in thousands): Year Ended December 31, 2023 2022 Deferred tax assets: Net operating loss carryforward $ 96,242 $ 85,182 Reserves and accruals 3,152 3,943 Depreciation and amortization 564 563 Capitalized R&D costs 5,962 3,840 Tax credit carryforwards 15,463 14,456 Stock-based compensation 1,143 2,064 Right-of-use lease liabilities 7,782 8,663 Total gross deferred tax assets 130,308 118,711 Valuation allowance on deferred tax assets ( 124,124 ) ( 107,893 ) Total deferred tax assets, net of valuation allowance 6,184 10,818 Deferred tax liabilities: Fixed assets and intangibles ( 54 ) ( 3,913 ) Right-of-use assets ( 6,836 ) ( 7,729 ) Total deferred tax liabilities ( 6,890 ) ( 11,642 ) Net deferred tax liability $ ( 706 ) $ ( 824 ) Deferred tax liability per balance sheet $ ( 841 ) $ ( 1,055 ) Less deferred tax assets included in other long-term assets 135 231 Net deferred tax liability $ ( 706 ) $ ( 824 ) |
Schedule of Summary of Valuation Allowance | A reconciliation of the beginning and ending amounts of the valuation allowance for the years ended December 31, 2023 and 2022 is as follows (in thousands): Valuation Allowance December 31, 2021 $ 141,087 Charges to earnings — Charges to other accounts ( 33,194 ) December 31, 2022 107,893 Charges to earnings — Charges to other accounts 16,231 December 31, 2023 $ 124,124 |
Schedule of Aggregate Changes in Balance of Gross Unrecognized Tax Benefits | The aggregate changes in the balance of the Company's gross unrecognized tax benefits during 2023, and 2022 were as follows (in thousands): December 31, 2021 $ 8,515 Increases in balances related to tax positions during a prior 154 Increases in balances related to tax positions taken during — Decreases in balances related to tax positions taken during prior ( 1,697 ) December 31, 2022 6,972 Increases in balances related to tax positions during a prior 105 Decreases in balances related to tax positions taken during ( 138 ) December 31, 2023 $ 6,939 |
Segment Reporting (Tables)
Segment Reporting (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Segment Reporting [Abstract] | |
Schedule of Business Segment Information | The Company's business segment information was as follows (in thousands): Year Ended December 31, 2023 2022 Revenue: Proteomics $ 63,883 $ 52,502 Genomics 42,457 45,446 Total revenue $ 106,340 $ 97,948 Gross profit: Proteomics $ 26,239 $ 20,041 Genomics 24,211 17,010 Total gross profit $ 50,450 $ 37,051 Depreciation & amortization: Proteomics $ 12,072 $ 12,223 Genomics 601 230 Total depreciation & amortization $ 12,673 $ 12,453 |
Restructuring and Related Cha_2
Restructuring and Related Charges (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Restructuring and Related Activities [Abstract] | |
Schedule of Restructuring Liabilities | The following table summarizes the change in the Company’s restructuring and other related liabilities for the years ended December 31, 2023 and 2022 (in thousands): Severance (1) Facility Other (2) Total Balance at December 31, 2021 $ — $ — $ — $ — Restructuring and related charges 5,849 2,885 998 9,732 Cash payments ( 1,835 ) ( 2,885 ) ( 979 ) ( 5,699 ) Balance at December 31, 2022 $ 4,014 $ — $ 19 $ 4,033 Restructuring and related charges 2,379 4,160 537 7,076 Cash payments ( 5,568 ) ( 4,160 ) ( 556 ) ( 10,284 ) Balance at December 31, 2023 $ 825 $ — $ — $ 825 (1) Restructuring liabilities are recorded in accrued compensation and related benefits on the consolidated balance sheets. (2) Other restructuring liabilities are comprised mainly of sublease commissions and are recorded in other accrued liabilities on the consolidated balance sheets. The Company’s restructuring and related charges by segment and corporate were as follows (in thousands): Year Ended December 31, 2023 2022 Restructuring: Proteomics $ 1,010 $ 1,363 Genomics 714 1,273 Corporate expenses 5,352 7,096 Total restructuring and related charges $ 7,076 $ 9,732 |
Summary of Significant Accoun_4
Summary of Significant Accounting Policies - Narrative (Details) | 12 Months Ended | ||
Apr. 04, 2022 USD ($) | Dec. 31, 2023 USD ($) Segment shares | Dec. 31, 2022 USD ($) | |
Schedule Of Significant Accounting Policies [Line Items] | |||
Realized gains and losses from sales of short-term investments | $ 0 | $ 0 | |
Advertising costs incurred | $ 2,000,000 | 3,900,000 | |
Number of reporting segments | Segment | 2 | ||
Loss on forward sale of Series B Preferred Stock | $ 0 | 60,081,000 | |
Loss on bridge loans | $ 0 | 13,719,000 | |
Repurchase of common stock (in shares) | shares | 2,709,703 | ||
Bridge Loans | |||
Schedule Of Significant Accounting Policies [Line Items] | |||
Loss on bridge loans | 13,700,000 | ||
Convertible Preferred Stock | |||
Schedule Of Significant Accounting Policies [Line Items] | |||
Sale of stock, consideration received on transaction | $ 225,000,000 | ||
Loss on forward sale of Series B Preferred Stock | $ 60,081,000 | $ 60,081,000 | |
Office furniture and fixtures | |||
Schedule Of Significant Accounting Policies [Line Items] | |||
Property and equipment, estimated useful lives | 5 years | ||
Minimum | Computer equipment and software | |||
Schedule Of Significant Accounting Policies [Line Items] | |||
Property and equipment, estimated useful lives | 3 years | ||
Minimum | Laboratory and manufacturing equipment | |||
Schedule Of Significant Accounting Policies [Line Items] | |||
Property and equipment, estimated useful lives | 2 years | ||
Maximum | Computer equipment and software | |||
Schedule Of Significant Accounting Policies [Line Items] | |||
Property and equipment, estimated useful lives | 4 years | ||
Maximum | Laboratory and manufacturing equipment | |||
Schedule Of Significant Accounting Policies [Line Items] | |||
Property and equipment, estimated useful lives | 7 years | ||
Product revenue | Minimum | |||
Schedule Of Significant Accounting Policies [Line Items] | |||
Terms of payment period | 30 days | ||
Product revenue | Maximum | |||
Schedule Of Significant Accounting Policies [Line Items] | |||
Terms of payment period | 60 days | ||
Service revenue | Minimum | |||
Schedule Of Significant Accounting Policies [Line Items] | |||
Performance obligation period | 1 year | ||
Service revenue | Maximum | |||
Schedule Of Significant Accounting Policies [Line Items] | |||
Performance obligation period | 3 years |
Summary of Significant Accoun_5
Summary of Significant Accounting Policies - Schedule of Potential Common Shares Excluded from Computations of Net Loss Per Share Attributed to Common Stockholders (Details) - shares | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
RSUs, PSUs, stock options and ESPP shares | 16,740,000 | 15,752,000 |
Series B Preferred Stock | 75,164,000 | 75,164,000 |
Total | 110,880,000 | 109,892,000 |
Maximum additional shares issuable (in shares) | 4,741,374 | |
2019 Notes | Convertible Debt | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
2019 and 2014 Notes | 18,966,000 | 18,966,000 |
2014 Notes | Convertible Debt | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
2019 and 2014 Notes | 10,000 | 10,000 |
NIH Contract - Narrative (Detai
NIH Contract - Narrative (Details) | Sep. 30, 2020 USD ($) |
Research and Development [Abstract] | |
Maximum contract value | $ 34,000,000 |
NIH Contract (Details)
NIH Contract (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Research and Development [Abstract] | ||
Cumulative amounts applied against depreciation expense for assets placed in service | $ (7,800) | $ (4,200) |
Cumulative amounts applied against depreciation expense for assets placed in service | (7,800) | (4,200) |
Carrying value of property and equipment, net | 14,400 | 18,000 |
Deferred grant income, non-current | $ 10,755 | $ 14,359 |
Business Combination - Narrativ
Business Combination - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 12 Months Ended | |
Jun. 30, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | |
Business Acquisition [Line Items] | |||
Share price (in dollars per share) | $ 2.21 | ||
Goodwill | $ 106,317 | $ 106,251 | |
Impairment of InstruNor developed technology intangible | $ 0 | 3,526 | |
InstruNor AS | Developed technology | |||
Business Acquisition [Line Items] | |||
Impairment of InstruNor developed technology intangible | $ 3,500 | $ 3,500 |
Revenue and Geographic Area - S
Revenue and Geographic Area - Schedule of Disaggregation of Revenue (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Disaggregation of Revenue [Line Items] | ||
Total revenue | $ 106,340 | $ 97,948 |
Americas | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 46,196 | 43,982 |
EMEA | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 36,201 | 33,136 |
Asia-Pacific | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 23,943 | 20,830 |
Instruments | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 37,459 | 25,664 |
Consumables | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 41,739 | 46,790 |
Product revenue | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 79,198 | 72,454 |
Service revenue | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 25,980 | 23,712 |
Total product and service revenue | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 105,178 | 96,166 |
Total other revenue | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | $ 1,162 | $ 1,782 |
Revenue and Geographic Area - N
Revenue and Geographic Area - Narrative (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Disaggregation of Revenue [Line Items] | ||
Total revenue | $ 106,340 | $ 97,948 |
Deferred revenue | 15,100 | $ 14,600 |
Revenue recognized | 10,600 | |
Additional advance payments received | $ 11,100 | |
Revenue from Contract with Customer | Customer Concentration Risk | One Genomics Customer | ||
Disaggregation of Revenue [Line Items] | ||
Concentration risk, percentage | 10% | 11% |
Revenue from Contract with Customer | Customer Concentration Risk | Five Largest Customers | ||
Disaggregation of Revenue [Line Items] | ||
Concentration risk, percentage | 24% | 19% |
Accounts Receivable | Customer Concentration Risk | Customer One | ||
Disaggregation of Revenue [Line Items] | ||
Concentration risk, percentage | 14% | 16% |
United States | Revenue from Contract with Customer | Geographic Concentration Risk | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | $ 44,100 | $ 41,000 |
Concentration risk, percentage | 42% | 42% |
China | Revenue from Contract with Customer | Geographic Concentration Risk | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | $ 15,800 | |
Concentration risk, percentage | 15% | 11% |
Revenue and Geographic Area - L
Revenue and Geographic Area - Long-lived Assets by Geographic Areas (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Segment Reporting Information [Line Items] | ||
Long-lived Assets | $ 54,850 | $ 59,535 |
United States | ||
Segment Reporting Information [Line Items] | ||
Long-lived Assets | 29,646 | 31,785 |
Singapore | ||
Segment Reporting Information [Line Items] | ||
Long-lived Assets | 17,097 | 21,178 |
Canada | ||
Segment Reporting Information [Line Items] | ||
Long-lived Assets | 6,231 | 5,394 |
Other Asia-Pacific | ||
Segment Reporting Information [Line Items] | ||
Long-lived Assets | 889 | 875 |
EMEA | ||
Segment Reporting Information [Line Items] | ||
Long-lived Assets | $ 987 | $ 303 |
Revenue and Geographic Area - P
Revenue and Geographic Area - Performance Obligations (Details) $ in Thousands | Dec. 31, 2023 USD ($) | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | ||
Remaining performance obligation | $ 24,060 | [1] |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | ||
Remaining performance obligation | $ 13,253 | [1] |
Revenue, remaining performance obligation, expected timing of satisfaction, period | 1 year | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01 | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | ||
Remaining performance obligation | $ 6,634 | [1] |
Revenue, remaining performance obligation, expected timing of satisfaction, period | 1 year | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01 | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | ||
Remaining performance obligation | $ 3,061 | [1] |
Revenue, remaining performance obligation, expected timing of satisfaction, period | 1 year | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-01-01 | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | ||
Remaining performance obligation | $ 1,112 | [1] |
Revenue, remaining performance obligation, expected timing of satisfaction, period | ||
[1] Expected revenue includes both billed amounts included in deferred revenue and unbilled amounts that are not reflected in the Company's consolidated financial statements and are subject to change if the Company's customers decide to cancel or modify their contracts. Purchase orders for instrument service contracts can generally be canceled without penalty before the service period begins. |
Revenue and Geographic Area -_2
Revenue and Geographic Area - Performance Obligation (Details1) $ in Thousands | Dec. 31, 2023 USD ($) | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | ||
Remaining performance obligation | $ 24,060 | [1] |
[1] Expected revenue includes both billed amounts included in deferred revenue and unbilled amounts that are not reflected in the Company's consolidated financial statements and are subject to change if the Company's customers decide to cancel or modify their contracts. Purchase orders for instrument service contracts can generally be canceled without penalty before the service period begins. |
Goodwill and Intangible Asset_3
Goodwill and Intangible Assets, net - Narrative (Details) - USD ($) | 3 Months Ended | 12 Months Ended | ||
Dec. 31, 2023 | Jun. 30, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | |
Finite-Lived Intangible Assets [Line Items] | ||||
Goodwill | $ 106,317,000 | $ 106,317,000 | $ 106,251,000 | |
Impairment of InstruNor developed technology intangible | 0 | 3,526,000 | ||
Impairment of goodwill | $ 0 | |||
Amortization of developed technology | 11,200,000 | 11,528,000 | ||
Developed technology | ||||
Finite-Lived Intangible Assets [Line Items] | ||||
Amortization of developed technology | $ 11,800,000 | 12,200,000 | ||
InstruNor AS | Developed technology | ||||
Finite-Lived Intangible Assets [Line Items] | ||||
Impairment of InstruNor developed technology intangible | $ 3,500,000 | $ 3,500,000 |
Goodwill and Intangible Asset_4
Goodwill and Intangible Assets, net - Changes in the Carrying Value of Goodwill by Segment (Details) $ in Thousands | 12 Months Ended |
Dec. 31, 2023 USD ($) | |
Goodwill [Roll Forward] | |
Balance as of December 31, 2022 | $ 106,251 |
Foreign currency translation | 66 |
Balance as of December 31, 2023 | 106,317 |
Proteomics | |
Goodwill [Roll Forward] | |
Balance as of December 31, 2022 | 85,752 |
Foreign currency translation | 46 |
Balance as of December 31, 2023 | 85,798 |
Genomics | |
Goodwill [Roll Forward] | |
Balance as of December 31, 2022 | 20,499 |
Foreign currency translation | 20 |
Balance as of December 31, 2023 | $ 20,519 |
Goodwill and Intangible Asset_5
Goodwill and Intangible Assets, net - Schedule of Finite-lived Intangible Assets (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Finite-Lived Intangible Assets [Line Items] | ||
Total | $ 1,407 | |
Developed technology | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Amount | 117,354 | $ 117,194 |
Accumulated Amortization and Impairment | (115,954) | (104,594) |
Total | $ 1,400 | $ 12,600 |
Weighted-Average Amortization Period | 10 years | 10 years |
Patents and licenses | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Amount | $ 11,250 | $ 11,247 |
Accumulated Amortization and Impairment | (11,243) | (10,669) |
Total | $ 7 | $ 578 |
Weighted-Average Amortization Period | 7 years | 7 years |
Goodwill and Intangible Asset_6
Goodwill and Intangible Assets, net - Future Amortization Expense (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Finite-Lived Intangible Assets [Line Items] | ||
2024 | $ 1,407 | |
Total | 1,407 | |
Developed Technology Amortization Expense | ||
Finite-Lived Intangible Assets [Line Items] | ||
2024 | 1,400 | |
Total | 1,400 | $ 12,600 |
Patents and Licenses Amortization Expense | ||
Finite-Lived Intangible Assets [Line Items] | ||
2024 | 7 | |
Total | $ 7 | $ 578 |
Balance Sheet Details - Summary
Balance Sheet Details - Summary of Cash and Cash Equivalents (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 |
Balance Sheet Related Disclosures [Abstract] | |||
Cash and cash equivalents | $ 51,704 | $ 81,309 | |
Restricted cash | 795 | 1,015 | |
Total cash, cash equivalents, and restricted cash | 52,499 | 82,324 | $ 29,467 |
Non-current restricted cash | $ 800 | $ 1,000 |
Balance Sheet Details - Invento
Balance Sheet Details - Inventories (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Balance Sheet Related Disclosures [Abstract] | ||
Raw materials | $ 15,539 | $ 16,866 |
Work-in-process | 282 | 945 |
Finished goods | 11,753 | 15,245 |
Total inventory, gross | 27,574 | 33,056 |
Allowance for excess and obsolete inventory | (7,041) | (11,583) |
Total inventories, net | $ 20,533 | $ 21,473 |
Balance Sheet Details - Propert
Balance Sheet Details - Property and Equipment (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Property, Plant and Equipment [Line Items] | ||
Property and equipment, gross | $ 57,342 | $ 53,069 |
Less accumulated depreciation and amortization | (35,489) | (29,029) |
Construction-in-progress | 2,334 | 1,612 |
Property and equipment, net | 24,187 | 25,652 |
Laboratory and manufacturing equipment | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, gross | 35,563 | 33,329 |
Leasehold improvements | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, gross | 13,785 | 12,234 |
Computer equipment and software | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, gross | 6,232 | 5,793 |
Office furniture and fixtures | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, gross | $ 1,762 | $ 1,713 |
Balance Sheet Details - Narrati
Balance Sheet Details - Narrative (Details) - USD ($) | 1 Months Ended | 12 Months Ended | |
Sep. 30, 2020 | Dec. 31, 2023 | Dec. 31, 2022 | |
Balance Sheet Related Disclosures [Abstract] | |||
Depreciation | $ 3,400,000 | $ 2,800,000 | |
Maximum contract value | $ 34,000,000 | ||
Capital expenditures | $ 22,200,000 | ||
Depreciation expenses | 3,600,000 | 3,500,000 | |
Accumulated depreciation expenses | 7,800,000 | 4,200,000 | |
Carrying value of assets | $ 14,400,000 | $ 18,000,000 |
Balance Sheet Details - Accrued
Balance Sheet Details - Accrued Compensation and Related Benefits (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Balance Sheet Related Disclosures [Abstract] | ||
Accrued incentive compensation | $ 7,337 | $ 1,170 |
Accrued vacation | 2,711 | 2,795 |
Accrued payroll taxes and other | 994 | 1,174 |
Accrued restructuring | 825 | 4,014 |
Accrued compensation and related benefits | $ 11,867 | $ 9,153 |
Balance Sheet Details - Other A
Balance Sheet Details - Other Accrued Liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Balance Sheet Related Disclosures [Abstract] | ||
Accrued commissions | $ 1,010 | $ 800 |
Accrued interest | 295 | 318 |
Accrued legal expenses | 964 | 349 |
Accrued taxes | 1,230 | 1,443 |
Uninvoiced receipts | 1,516 | 1,078 |
Accrued warranties | 2,593 | 678 |
Customer advances | 447 | 577 |
Accrued restructuring | 0 | 19 |
Accrued other | 1,097 | 913 |
Other accrued liabilities | $ 9,152 | $ 6,175 |
Debt - Schedule of Carrying Val
Debt - Schedule of Carrying Value of Debt (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Debt Instrument [Line Items] | ||
Total debt | $ 63,513 | $ 64,892 |
Line of credit outstanding | 8,414 | |
Convertible Debt | ||
Debt Instrument [Line Items] | ||
Total debt | 55,099 | 54,615 |
Secured Debt | ||
Debt Instrument [Line Items] | ||
Term loan, non-current | 3,414 | 8,194 |
Term loan, current | 5,000 | 2,083 |
2014 Notes | Convertible Debt | ||
Debt Instrument [Line Items] | ||
Total debt | 569 | 568 |
2019 Notes, non-current | Convertible Debt | ||
Debt Instrument [Line Items] | ||
Total debt | 0 | 54,047 |
2019 Notes, current | Convertible Debt | ||
Debt Instrument [Line Items] | ||
Total debt | $ 54,530 | $ 0 |
Debt - Narrative (Details)
Debt - Narrative (Details) | 1 Months Ended | 2 Months Ended | 12 Months Ended | ||||||
Aug. 02, 2018 USD ($) | Nov. 30, 2019 USD ($) $ / shares shares | Feb. 28, 2014 | Mar. 31, 2022 USD ($) | Dec. 31, 2023 USD ($) MonthlyInstallment | Dec. 31, 2022 USD ($) | Apr. 04, 2022 USD ($) | Jan. 23, 2022 USD ($) | Aug. 02, 2021 USD ($) | |
Debt Instrument [Line Items] | |||||||||
Principal amount | $ 7,917,000 | ||||||||
Line of credit outstanding | 8,414,000 | ||||||||
Convertible Debt | 2014 Notes | |||||||||
Debt Instrument [Line Items] | |||||||||
Principal amount | $ 1,100,000 | ||||||||
Convertible Debt | 2019 Notes | |||||||||
Debt Instrument [Line Items] | |||||||||
Aggregate principal amount | 55,000,000 | ||||||||
Proceeds from issuance of debt | $ 52,700,000 | ||||||||
Interest rate on notes | 5.25% | ||||||||
Initial conversion rate of notes | 0.3448276 | ||||||||
Debt conversion, converted instrument, shares issued | shares | 344.8276 | ||||||||
Initial conversion price of stock (in dollars per share) | $ / shares | $ 2.9 | ||||||||
Convertible Debt | Redemption, Period Two | 2019 Notes | |||||||||
Debt Instrument [Line Items] | |||||||||
Debt redemption conditioned upon common stock value exceeding a percentage of the conversion price | 130% | ||||||||
Convertible Debt | Redemption, Period Three | 2014 Notes | |||||||||
Debt Instrument [Line Items] | |||||||||
Debt instrument redemption price | 100% | ||||||||
Secured Debt | |||||||||
Debt Instrument [Line Items] | |||||||||
Aggregate principal amount | $ 7,900,000 | $ 10,000,000 | |||||||
Interest rate on notes | 4% | ||||||||
Convertible debt | $ 600,000 | ||||||||
Term loan | $ 8,400,000 | ||||||||
Term loan advances percentage | 6.50% | ||||||||
Number of installments | MonthlyInstallment | 24 | ||||||||
Term loan, non-current | $ 3,414,000 | $ 8,194,000 | |||||||
Secured Debt | Prime Rate | |||||||||
Debt Instrument [Line Items] | |||||||||
Additional interest rate | 0.75% | ||||||||
Line of Credit | Revolving Credit Facility | |||||||||
Debt Instrument [Line Items] | |||||||||
Borrowing base | $ 15,000,000 | ||||||||
Percentage of eligible receivables | 85% | ||||||||
Percentage of eligible inventory | 50% | ||||||||
Line of credit outstanding | $ 0 | ||||||||
Bridge Loans | |||||||||
Debt Instrument [Line Items] | |||||||||
Debt instrument, face amount, per instrument | $ 25,000,000 | ||||||||
Change in fair value of Bridge Loans | $ 13,700,000 | ||||||||
Fair value of Bridge Loans | $ 38,700,000 | $ 25,000,000 |
Debt - Future Minimum Payments
Debt - Future Minimum Payments under Term Loan Facility including End of Term Fee Payment (Details) $ in Thousands | 12 Months Ended |
Dec. 31, 2023 USD ($) | |
Debt Disclosure [Abstract] | |
2024 | $ 5,000 |
2025 | 2,917 |
Total long term debt | 7,917 |
End of term fee and debt issuance costs | 497 |
Total Term Loan Facility | $ 8,414 |
Commitments and Contingencies -
Commitments and Contingencies - Narrative (Details) - USD ($) $ in Millions | 1 Months Ended | 12 Months Ended | |
Feb. 28, 2023 | Aug. 31, 2022 | Dec. 31, 2023 | |
Lessee, Lease, Description [Line Items] | |||
Renewal term | 5 years | ||
Lease expiration date | Apr. 30, 2030 | ||
Lease option to extend | contains an option to extend the lease | ||
Lessee, Operating Lease, Existence of Option to Extend [true false] | true | ||
Lease option to termination | along with termination options | ||
Lessee, Operating Lease, Existence of Option to Terminate [true false] | true | ||
Purchase commitment due in the next year | $ 9.7 | ||
South San Francisco | |||
Lessee, Lease, Description [Line Items] | |||
Percentage of headquarters subleased space | 25% | 25% | |
Lessor, operating lease, term of contract | 77 months | 39 months | |
Lessor, operating lease, remaining term of contract | 24 months | ||
Lessor, operating lease, sublease income expected | $ 9.1 | $ 4.8 | |
Corporate Headquarters (18th Floor) | South San Francisco | |||
Lessee, Lease, Description [Line Items] | |||
Lessor, operating lease, sublease income expected | $ 2.9 | ||
Corporate Headquarters (21st Floor) | |||
Lessee, Lease, Description [Line Items] | |||
Lessor, operating lease, sublease income expected | $ 9 | ||
Minimum | |||
Lessee, Lease, Description [Line Items] | |||
Remaining lease term | 1 year | ||
Maximum | |||
Lessee, Lease, Description [Line Items] | |||
Remaining lease term | 6 years |
Commitments and Contingencies_2
Commitments and Contingencies - Schedule of Operating Leases (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Leases [Abstract] | ||
Weighted average remaining lease term (in years) | 5 years 10 months 24 days | 6 years 9 months 18 days |
Weighted average discount rate per annum | 11.80% | 11.80% |
Operating lease cost (including variable costs) | $ 11,159 | $ 10,917 |
Variable costs (including non-lease components) | 3,164 | 2,930 |
Sublease income | 2,679 | 189 |
Cash paid for amounts included in the measurement of operating lease liabilities | $ 7,931 | $ 7,540 |
Commitments and Contingencies_3
Commitments and Contingencies - Operating Lease Maturity (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Minimum Lease Payments for Operating Leases | ||
2024 | $ 8,086 | |
2025 | 8,135 | |
2026 | 7,821 | |
2027 | 7,395 | |
2028 | 7,355 | |
Thereafter | 10,225 | |
Total future minimum payments (receipts) | 49,017 | |
Imputed interest | (14,320) | |
Total operating lease liabilities | 34,697 | |
Less: current portion of operating lease liabilities | 4,323 | $ 3,682 |
Operating lease liabilities, net of current portion | 30,374 | $ 34,081 |
Sublease Income | ||
2024 | (2,877) | |
2025 | (2,952) | |
2026 | (1,381) | |
2027 | (1,430) | |
2028 | (1,480) | |
Thereafter | (2,058) | |
Total future minimum payments (receipts) | (12,178) | |
Net Minimum Lease Payments for Operating Leases | ||
2024 | 5,209 | |
2025 | 5,183 | |
2026 | 6,440 | |
2027 | 5,965 | |
2028 | 5,875 | |
Thereafter | 8,167 | |
Total future minimum payments (receipts) | $ 36,839 |
Fair Value of Financial Instr_3
Fair Value of Financial Instruments - Summary of Recurring Basis within the Fair Value Hierarchy (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | ||
Short-term investments | $ 98,576 | $ 138,369 |
Fair Value, Recurring | ||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | ||
Cash and cash equivalents | 35,385 | 53,894 |
Short-term investments | 63,191 | 84,475 |
Total assets measured at fair value | 98,576 | 138,369 |
Fair Value, Recurring | Quoted Prices in Active Markets For Identical Assets (Level 1) | ||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | ||
Cash and cash equivalents | 35,385 | 53,894 |
Short-term investments | 0 | 84,475 |
Total assets measured at fair value | 35,385 | 138,369 |
Fair Value, Recurring | Significant Other Observable Inputs (Level 2) | ||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | ||
Cash and cash equivalents | 0 | 0 |
Short-term investments | 63,191 | 0 |
Total assets measured at fair value | 63,191 | 0 |
Fair Value, Recurring | Significant Unobservable Inputs (Level 3) | ||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | ||
Cash and cash equivalents | 0 | 0 |
Short-term investments | 0 | 0 |
Total assets measured at fair value | 0 | 0 |
U.S. treasury securities | Fair Value, Recurring | ||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | ||
Short-term investments | 63,191 | 84,475 |
U.S. treasury securities | Fair Value, Recurring | Quoted Prices in Active Markets For Identical Assets (Level 1) | ||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | ||
Short-term investments | 0 | 84,475 |
U.S. treasury securities | Fair Value, Recurring | Significant Other Observable Inputs (Level 2) | ||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | ||
Short-term investments | 63,191 | 0 |
U.S. treasury securities | Fair Value, Recurring | Significant Unobservable Inputs (Level 3) | ||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | ||
Short-term investments | 0 | 0 |
Money market funds | Fair Value, Recurring | ||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | ||
Cash and cash equivalents | 35,385 | 53,894 |
Money market funds | Fair Value, Recurring | Quoted Prices in Active Markets For Identical Assets (Level 1) | ||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | ||
Cash and cash equivalents | 35,385 | 53,894 |
Money market funds | Fair Value, Recurring | Significant Other Observable Inputs (Level 2) | ||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | ||
Cash and cash equivalents | 0 | 0 |
Money market funds | Fair Value, Recurring | Significant Unobservable Inputs (Level 3) | ||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | ||
Cash and cash equivalents | $ 0 | $ 0 |
Fair Value of Financial Instr_4
Fair Value of Financial Instruments - Schedule of Available-for-Sale Securities (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | ||
Amortized Cost | $ 98,554 | $ 138,871 |
Unrealized Gains | 22 | 0 |
Unrealized Losses | 0 | (502) |
Estimated Fair Value | 98,576 | 138,369 |
Cash and cash equivalents | ||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | ||
Amortized Cost | 35,385 | 53,894 |
Unrealized Gains | 0 | 0 |
Unrealized Losses | 0 | 0 |
Estimated Fair Value | 35,385 | 53,894 |
Short-term investments | ||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | ||
Amortized Cost | 63,169 | 84,977 |
Unrealized Gains | 22 | 0 |
Unrealized Losses | 0 | (502) |
Estimated Fair Value | 63,191 | 84,475 |
Money market funds | Cash and cash equivalents | ||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | ||
Amortized Cost | 35,385 | 53,894 |
Unrealized Gains | 0 | 0 |
Unrealized Losses | 0 | 0 |
Estimated Fair Value | 35,385 | 53,894 |
U.S. treasury securities | Short-term investments | ||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | ||
Amortized Cost | 63,169 | 84,977 |
Unrealized Gains | 22 | 0 |
Unrealized Losses | 0 | (502) |
Estimated Fair Value | $ 63,191 | $ 84,475 |
Fair Value of Financial Instr_5
Fair Value of Financial Instruments - Narrative (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Available-for-sale securities held | $ 0 | |
Amortization cost before recovery | 0 | |
Allowance for credit loss | 0 | |
Fair Value | Significant Unobservable Inputs (Level 3) | Convertible Debt | 2019 Notes | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Estimated fair value | $ 58,200,000 | $ 48,400,000 |
Mezzanine Equity - Narrative (D
Mezzanine Equity - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions | Apr. 04, 2022 | Dec. 31, 2023 | Dec. 31, 2022 |
Debt Instrument [Line Items] | |||
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 | |
Series B Preferred Stock | |||
Debt Instrument [Line Items] | |||
Sale of stock, consideration received on transaction | $ 225 | ||
Shares sold (in shares) | 225,000 | ||
Debt conversion, converted instrument, shares issued | 30,559 | ||
Shares issued (in shares) | 255,559 | ||
Series B Preferred Stock | Casdin | |||
Debt Instrument [Line Items] | |||
Shares sold (in shares) | 112,500 | ||
Preferred stock, par value (in dollars per share) | $ 0.001 | ||
Price per share (in dollars per share) | $ 1,000 | ||
Series B Preferred Stock | Viking | |||
Debt Instrument [Line Items] | |||
Shares sold (in shares) | 112,500 | ||
Preferred stock, par value (in dollars per share) | $ 0.001 | ||
Price per share (in dollars per share) | $ 1,000 |
Mezzanine Equity - Preferred St
Mezzanine Equity - Preferred Stock (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Shareholders' Equity [Line Items] | ||
Proceeds from Purchase Agreements | $ 0 | $ 225,000 |
Proceeds from Bridge Loans | 0 | 25,000 |
Change in fair value of Forward Purchase Agreements | 0 | 60,081 |
Total Series B Redeemable Preferred Stock | 311,253 | 311,253 |
Series B Preferred Stock | ||
Shareholders' Equity [Line Items] | ||
Proceeds from Purchase Agreements | 225,000 | 225,000 |
Proceeds from Bridge Loans | 25,000 | 25,000 |
Change in fair value of Forward Purchase Agreements | 60,081 | 60,081 |
Change in fair value of Bridge Loans | 13,719 | 13,719 |
Less equity issuance costs | (12,547) | (12,547) |
Total Series B Redeemable Preferred Stock | $ 311,253 | $ 311,253 |
Shareholders' Deficit - Narrati
Shareholders' Deficit - Narrative (Details) - USD ($) | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Nov. 23, 2022 | |
Equity [Abstract] | |||
Stock repurchase program, authorized amount | $ 20,000,000 | ||
Repurchase of common stock (in shares) | 2,709,703 | ||
Share repurchase amount | $ 5,414,000 | $ 563,000 | |
Treasury stock acquired, average cost per share (in dollars per share) | $ 1.98 |
Shareholders' Deficit - Schedul
Shareholders' Deficit - Schedule of Shares Reserved for Future Issuance Under Equity Compensation Plans (Details) - shares shares in Thousands | Dec. 31, 2023 | Apr. 30, 2022 |
Class of Stock [Line Items] | ||
Number of remaining securities available for future issuance (in shares) | 6,445 | |
2022 Inducement Equity Incentive Plan | ||
Class of Stock [Line Items] | ||
Number of remaining securities available for future issuance (in shares) | 208 | 9,500 |
2011 Equity Incentive Plan | ||
Class of Stock [Line Items] | ||
Number of remaining securities available for future issuance (in shares) | 4,656 | |
2017 Inducement Award Plan | ||
Class of Stock [Line Items] | ||
Number of remaining securities available for future issuance (in shares) | 0 | |
2017 Employee Stock Purchase Plan | ||
Class of Stock [Line Items] | ||
Number of remaining securities available for future issuance (in shares) | 1,581 | |
Securities To Be Issued Upon Exercise Of Options | ||
Class of Stock [Line Items] | ||
Securities to be issued (in shares) | 9,294 | |
Securities To Be Issued Upon Exercise Of Options | 2022 Inducement Equity Incentive Plan | ||
Class of Stock [Line Items] | ||
Securities to be issued (in shares) | 7,595 | |
Securities To Be Issued Upon Exercise Of Options | 2011 Equity Incentive Plan | ||
Class of Stock [Line Items] | ||
Securities to be issued (in shares) | 1,640 | |
Securities To Be Issued Upon Exercise Of Options | 2017 Inducement Award Plan | ||
Class of Stock [Line Items] | ||
Securities to be issued (in shares) | 59 | |
Securities To Be Issued Upon Exercise Of Options | 2017 Employee Stock Purchase Plan | ||
Class of Stock [Line Items] | ||
Securities to be issued (in shares) | 0 | |
Restricted Stock Units | ||
Class of Stock [Line Items] | ||
Securities to be issued (in shares) | 7,243 | |
Restricted Stock Units | 2022 Inducement Equity Incentive Plan | ||
Class of Stock [Line Items] | ||
Securities to be issued (in shares) | 1,277 | |
Restricted Stock Units | 2011 Equity Incentive Plan | ||
Class of Stock [Line Items] | ||
Securities to be issued (in shares) | 5,964 | |
Restricted Stock Units | 2017 Inducement Award Plan | ||
Class of Stock [Line Items] | ||
Securities to be issued (in shares) | 2 | |
Restricted Stock Units | 2017 Employee Stock Purchase Plan | ||
Class of Stock [Line Items] | ||
Securities to be issued (in shares) | 0 |
Stock-based Compensation - Narr
Stock-based Compensation - Narrative (Details) - USD ($) $ / shares in Units, shares in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Apr. 30, 2022 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Number of remaining securities available for future issuance (in shares) | 6,445 | ||
Share price (in dollars per share) | $ 2.21 | ||
2011 Equity Incentive Plan | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Number of remaining securities available for future issuance (in shares) | 4,656 | ||
Equity Incentive Plan | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Aggregate intrinsic value, vested and released | $ 100,000 | $ 0 | |
Total unrecognized compensation cost related to stock-based compensation arrangements | $ 12,400,000 | ||
Weighted average remaining contractual terms | 2 years 3 months 18 days | ||
2017 Employee Stock Purchase Plan | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Number of remaining securities available for future issuance (in shares) | 1,581 | ||
2022 Inducement Equity Incentive Plan | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Number of remaining securities available for future issuance (in shares) | 208 | 9,500 | |
Tranche One | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Number of months over which options vest ratably | 36 months | ||
Tranche Two | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Number of months over which options vest ratably | 48 months | ||
Restricted Stock Units (RSUs) | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Award vesting period | 4 years | ||
Award vesting percentage | 25% | ||
Total unrecognized compensation cost related to stock-based compensation arrangements | $ 13,900,000 | ||
Weighted average remaining contractual terms | 2 years 6 months | ||
Restricted Stock Units (RSUs) | Tranche One | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Rate at which outstanding options vest on the first anniversary of the option grant date | 25% | ||
Share-Based Payment Arrangement | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Expiration period | 10 years | ||
Stock option grants exercise price minimum percentage on fair market value | 100% | ||
Performance Shares | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Performance period | 3 years | ||
Performance Shares | Minimum | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Percentage of performance period | 0% | ||
Performance Shares | Maximum | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Percentage of performance period | 200% |
Stock-based Compensation - Rest
Stock-based Compensation - Restricted and Performance Stock Units (Details) shares in Thousands | 12 Months Ended |
Dec. 31, 2023 $ / shares shares | |
Restricted Stock Units (RSUs) | |
Number of Nonvested and Outstanding Units | |
Beginning balance (in shares) | shares | 7,120 |
Granted (in shares) | shares | 3,728 |
Released (in shares) | shares | (2,970) |
Forfeited (in shares) | shares | (945) |
Ending balance (in shares) | shares | 6,933 |
Weighted-Average Grant Date Fair Value per Share | |
Beginning balance (in dollars per share) | $ / shares | $ 2.58 |
Granted (in dollars per share) | $ / shares | 2.32 |
Released (in dollars per share) | $ / shares | 2.68 |
Forfeited (in dollars per share) | $ / shares | 2.17 |
Ending balance (in dollars per share) | $ / shares | $ 2.46 |
Performance Shares | |
Number of Nonvested and Outstanding Units | |
Beginning balance (in shares) | shares | 453 |
Granted (in shares) | shares | 309 |
Released (in shares) | shares | (52) |
Performance adjustment for 2020 awards (in shares) | shares | shares | (401) |
Ending balance (in shares) | shares | 309 |
Weighted-Average Grant Date Fair Value per Share | |
Beginning balance (in dollars per share) | $ / shares | $ 4.81 |
Granted (in dollars per share) | $ / shares | 2.42 |
Released (in dollars per share) | $ / shares | 9.6 |
Performance adjustment for 2020 awards (in shares) | shares | $ / shares | 4.19 |
Ending balance (in dollars per share) | $ / shares | $ 2.42 |
Stock-based Compensation - Stoc
Stock-based Compensation - Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Number of Options | ||
Beginning balance (in shares) | 7,882 | |
Options granted (in shares) | 2,609 | |
Option exercised (in shares) | (44) | |
Options cancelled (in shares) | (1,153) | |
Ending balance (in shares) | 9,294 | 7,882 |
Vested (in shares) | 3,497 | |
Unvested awards (in shares) | 5,797 | |
Weighted-Average Exercise Price per Option | ||
Beginning balance (in dollars per share) | $ 4.43 | |
Options granted (in dollars per share) | 2.57 | |
Options exercised (in dollars per share) | 1.84 | |
Options cancelled (in dollars per share) | 6.84 | |
Ending balance (in dollars per share) | 3.62 | $ 4.43 |
Vested (in dollars per share) | 3.98 | |
Unvested awards (in dollars per share) | $ 3.4 | |
Weighted- Average Remaining Contractual Life (in Years) | ||
Contractual term | 8 years 6 months | 7 years 10 months 24 days |
Vested | 8 years 2 months 12 days | |
Unvested awards | 8 years 8 months 12 days | |
Aggregate Intrinsic Value | ||
Outstanding | $ 439 | $ 0 |
Vested | 78 | |
Unvested awards | $ 361 | |
Share price (in usd per share) | $ 2.21 |
Stock-based Compensation - Weig
Stock-based Compensation - Weighted-average Assumptions (Details) - $ / shares | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Share-Based Payment Arrangement [Abstract] | ||
Weighted average expected volatility | 97.10% | 91.80% |
Weighted average expected term | 4 years 8 months 12 days | 4 years 3 months 18 days |
Weighted average risk-free interest rate | 3.90% | 2.60% |
Dividend yield | 0% | 0% |
Weighted-average fair value per share (in dollars per share) | $ 1.49 | $ 2.21 |
Stock-based Compensation - St_2
Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Total stock-based compensation | $ 13,123 | $ 14,880 |
Cost of product revenue | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Total stock-based compensation | 811 | 592 |
Research and development expense | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Total stock-based compensation | 1,671 | 2,481 |
Selling, general and administrative expense | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Total stock-based compensation | $ 10,641 | $ 11,807 |
Income Taxes - Loss Before Inco
Income Taxes - Loss Before Income Taxes (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Income Tax Disclosure [Abstract] | ||
Domestic | $ (40,587) | $ (174,041) |
International | (33,617) | (18,887) |
Loss before income taxes | $ (74,204) | $ (192,928) |
Income Taxes - Components of Pr
Income Taxes - Components of Provision for Income Taxes (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Current: | ||
Federal | $ 0 | $ 0 |
State | (197) | (87) |
Foreign | (373) | (405) |
Total current tax expense | (570) | (492) |
Deferred: | ||
Federal | 0 | 0 |
State | 0 | 0 |
Foreign | 118 | 3,322 |
Total deferred benefit | 118 | 3,322 |
Total benefit (expense) from income taxes | $ (452) | $ 2,830 |
Income Taxes - Reconciliation o
Income Taxes - Reconciliation of Income Taxes at Statutory Rate (Details) | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Income Tax Disclosure [Abstract] | ||
Tax benefit at federal statutory rate | 21% | 21% |
State tax expense, net of federal benefit | 1.30% | 0.80% |
Foreign tax expense | 8.10% | 0.80% |
NOL carryforwards expiring unutilized | (5.50%) | (22.80%) |
Change in valuation allowance | (21.90%) | 17.10% |
Federal R&D credit | 0.20% | 0.20% |
Unrecognized tax benefit | 0% | 0.90% |
Non-deductible interest/premium | 0% | (0.30%) |
Non-deductible loss on Forward Sale of Preferred Stock and Bridge Loans | 0% | (8.00%) |
R&D tax credits expiring unutilized | 0% | (5.20%) |
Transaction costs | (1.50%) | 0% |
Executive stock-based compensation | (2.60%) | (0.80%) |
Return to provision | 2.50% | 0% |
Other, net | (2.00%) | (2.20%) |
Effective tax rate | (0.40%) | 1.50% |
Income Taxes - Components of De
Income Taxes - Components of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Deferred tax assets: | ||
Net operating loss carryforward | $ 96,242 | $ 85,182 |
Reserves and accruals | 3,152 | 3,943 |
Depreciation and amortization | 564 | 563 |
Capitalized R&D costs | 5,962 | 3,840 |
Tax credit carryforwards | 15,463 | 14,456 |
Stock-based compensation | 1,143 | 2,064 |
Right-of-use lease liabilities | 7,782 | 8,663 |
Total gross deferred tax assets | 130,308 | 118,711 |
Valuation allowance on deferred tax assets | (124,124) | (107,893) |
Total deferred tax assets, net of valuation allowance | 6,184 | 10,818 |
Deferred tax liabilities: | ||
Fixed assets and intangibles | (54) | (3,913) |
Right-of-use assets | (6,836) | (7,729) |
Total deferred tax liabilities | (6,890) | (11,642) |
Net deferred tax liability | (706) | (824) |
Deferred tax liability per balance sheet | (841) | (1,055) |
Less deferred tax assets included in other long-term assets | $ 135 | $ 231 |
Income Taxes - Narrative (Detai
Income Taxes - Narrative (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2022 | Dec. 31, 2023 | |
Income Taxes [Line Items] | ||
Valuation allowance | $ 107,893,000 | $ 124,124,000 |
Unrecognized tax benefits, that if recognized would affect effective tax rate | 0 | |
Unrecognized tax benefits, decrease resulting from prior period tax positions | $ 1,697,000 | |
Domestic Tax Authority | ||
Income Taxes [Line Items] | ||
Operating loss carryforward | 363,500,000 | |
Domestic Tax Authority | Research Tax Credit Carryforward | ||
Income Taxes [Line Items] | ||
Tax credit carryforward | 500,000 | |
State and Local Jurisdiction | ||
Income Taxes [Line Items] | ||
Operating loss carryforward | 220,400,000 | |
State and Local Jurisdiction | Research Tax Credit Carryforward | ||
Income Taxes [Line Items] | ||
Tax credit carryforward | 14,000,000 | |
Foreign Tax Authority | ||
Income Taxes [Line Items] | ||
Operating loss carryforward | 36,600,000 | |
Tax credit carryforward | $ 6,900,000 |
Income Taxes - Valuation Allowa
Income Taxes - Valuation Allowance (Details) - Valuation Allowance, Deferred Tax Asset - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Valuation Allowances [Roll Forward] | ||
Beginning balance | $ 107,893 | $ 141,087 |
Charges to earnings | 0 | 0 |
Charges to other accounts | 16,231 | (33,194) |
Ending balance | $ 124,124 | $ 107,893 |
Income Taxes - Aggregate Change
Income Taxes - Aggregate Changes in Balance of Gross Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] | ||
Beginning balance | $ 6,972 | $ 8,515 |
Increases in balances related to tax positions during a prior period | 105 | 154 |
Increases in balances related to tax positions taken during current period | 0 | |
Decreases in balances related to tax positions taken during current period | (138) | |
Decreases in balances related to tax positions taken during prior period | (1,697) | |
Ending balance | $ 6,939 | $ 6,972 |
Segment Reporting - Narrative (
Segment Reporting - Narrative (Details) | 12 Months Ended |
Dec. 31, 2023 Segment | |
Segment Reporting Information [Line Items] | |
Number of reporting segments | 2 |
Segment Reporting - Schedule of
Segment Reporting - Schedule of Business Segment Information (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Segment Reporting Information [Line Items] | ||
Total revenue | $ 106,340 | $ 97,948 |
Gross profit | 50,450 | 37,051 |
Depreciation & amortization | 12,673 | 12,453 |
Proteomics | ||
Segment Reporting Information [Line Items] | ||
Total revenue | 63,883 | 52,502 |
Gross profit | 26,239 | 20,041 |
Depreciation & amortization | 12,072 | 12,223 |
Genomics | ||
Segment Reporting Information [Line Items] | ||
Total revenue | 42,457 | 45,446 |
Gross profit | 24,211 | 17,010 |
Depreciation & amortization | $ 601 | $ 230 |
Restructuring and Related Cha_3
Restructuring and Related Charges - Narrative (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Restructuring Cost and Reserve [Line Items] | ||
Restructuring and related charges | $ 7,076 | $ 9,732 |
Restructuring and Related Cha_4
Restructuring and Related Charges - Summary of the Changes in Our Restructuring and Other Related Liabilities (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Restructuring Reserve [Roll Forward] | ||
Beginning balance | $ 4,033 | $ 0 |
Restructuring and related charges | 7,076 | 9,732 |
Cash payments | (10,284) | (5,699) |
Ending balance | 825 | 4,033 |
Severance and other employee-related benefits | ||
Restructuring Reserve [Roll Forward] | ||
Beginning balance | 4,014 | 0 |
Restructuring and related charges | 2,379 | 5,849 |
Cash payments | (5,568) | (1,835) |
Ending balance | 825 | 4,014 |
Facility Costs | ||
Restructuring Reserve [Roll Forward] | ||
Beginning balance | 0 | 0 |
Restructuring and related charges | 4,160 | 2,885 |
Cash payments | (4,160) | (2,885) |
Ending balance | 0 | 0 |
Other | ||
Restructuring Reserve [Roll Forward] | ||
Beginning balance | 19 | 0 |
Restructuring and related charges | 537 | 998 |
Cash payments | (556) | (979) |
Ending balance | $ 0 | $ 19 |
Restructuring and Related Cha_5
Restructuring and Related Charges - Restructuring and Other Efficiency Costs (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Restructuring Cost and Reserve [Line Items] | ||
Total restructuring and other related costs | $ 7,076 | $ 9,732 |
Corporate expenses | ||
Restructuring Cost and Reserve [Line Items] | ||
Total restructuring and other related costs | 5,352 | 7,096 |
Proteomics | Operating segments | ||
Restructuring Cost and Reserve [Line Items] | ||
Total restructuring and other related costs | 1,010 | 1,363 |
Genomics | Operating segments | ||
Restructuring Cost and Reserve [Line Items] | ||
Total restructuring and other related costs | $ 714 | $ 1,273 |
401(K) Plan - Narrative (Detail
401(K) Plan - Narrative (Details) - USD ($) | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2019 | |
Defined Benefit Plan Disclosure [Line Items] | |||
Percent of employee match | 100% | ||
Maximum annual employee contribution matched by employer | $ 3,000 | ||
Employer matching contributions expense | $ 500,000 | $ 600,000 | |
Maximum | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Percentage of employees eligible compensation | 90% |
Subsequent Event - Narrative (D
Subsequent Event - Narrative (Details) - Subsequent Event - Common Stock | Jan. 05, 2024 |
Combined Company | |
Subsequent Event [Line Items] | |
Equity ownership percentage | 57% |
Combined Subsidiaries | |
Subsequent Event [Line Items] | |
Equity ownership percentage | 43% |
SomaLogic Inc. | |
Subsequent Event [Line Items] | |
Exchange ratio | 1.11% |